fourth
intern
symposium
respiratori
viral
infect
conven
macra
group
new
york
ny
netherland
antil
novemb
decemb
symposium
provid
annual
forum
virologist
vaccinologist
clinician
pharmacologist
public
health
specialist
discuss
recent
advanc
respiratori
viru
research
interdisciplinari
fashion
kaiser
et
al
munoz
et
al
schmidt
et
al
spectrum
discuss
rang
basic
virolog
pathogenesi
epidemiolog
immunolog
manag
strategi
particular
attent
vaccin
antivir
econom
issu
meet
chair
frederick
hayden
univers
virginia
albert
osterhau
career
enjoy
sustain
interest
acut
respiratori
diseas
specif
rhinoviru
graduat
univers
virginia
school
medicin
year
dr
william
mogabgab
work
great
lake
naval
train
station
report
discoveri
first
rhinoviru
strain
later
number
rhinoviru
type
pelon
et
al
earlier
import
epidemiolog
studi
cold
conduct
england
dr
christoph
andrew
david
tyrrel
us
studi
serious
hamper
lack
virolog
frost
gover
andrew
dingl
et
al
discoveri
rhinoviru
ad
greatli
abil
investig
studi
cold
also
becam
import
influenc
career
follow
resid
intern
medicin
case
western
reserv
univers
enter
us
armi
medic
corp
station
fort
dix
nj
respons
care
mani
hundr
recruit
adenoviru
ard
observ
research
conduct
ard
dr
harri
rose
columbia
univers
edward
busher
walter
reed
armi
institut
research
use
new
excit
techniqu
tissu
cultur
return
univers
virginia
join
dr
william
jordan
author
highli
regard
cleveland
famili
studi
minor
ill
home
dr
jordan
move
charlottesvil
chair
depart
prevent
medicin
continu
conduct
research
common
cold
period
dr
leonard
hayflick
wistar
institut
develop
wi
strain
human
embryon
lung
cell
found
grow
rhinoviru
effici
ideal
epidemiolog
studi
hayflick
moorehead
dr
jordan
began
studi
acut
respiratori
diseas
approxim
employe
eastern
region
offic
state
farm
insur
compani
work
support
commiss
acut
respiratori
diseas
arm
forc
epidemiolog
board
vaccin
develop
branch
nation
institut
allergi
infecti
diseas
insur
employe
maintain
daili
symptom
record
suppli
specimen
viral
cultur
serolog
studi
eventu
continu
year
nurs
monitor
employe
weekli
schedul
ensur
accur
record
data
studi
employ
cell
cultur
viral
identif
rhinoviru
account
cold
give
rate
rhinoviru
cold
per
person
per
year
attack
rate
consist
earlier
studi
young
adult
conduct
chicago
dr
dorothi
hamr
hamr
et
al
agespecif
rate
infect
higher
children
adult
season
variat
rhinoviru
attack
rate
also
observ
charlottesvil
popul
result
consist
larg
fall
peak
ill
associ
rhinoviru
interest
yearli
rhinoviru
outbreak
coincid
time
recurr
peak
respiratori
ill
identifi
year
earlier
dr
wade
hampton
frost
graduat
univers
virginia
first
dean
school
public
health
john
hopkin
univers
detail
daili
symptom
pattern
rhinoviru
cold
also
obtain
insur
compani
data
serotyp
viral
isol
becam
great
challeng
differ
rhinoviru
type
discov
earli
plastic
microtit
plate
toxic
cell
system
develop
use
bottom
small
glass
tube
provid
well
grow
cell
cultur
gwaltney
rhinoviru
serotyp
eventu
done
use
serum
pool
put
togeth
combinatori
system
new
serotyp
identifi
charlottesvil
gwaltney
et
al
epidemiolog
studi
us
england
lead
discoveri
mani
new
rhinoviru
serotyp
number
eventu
reach
kapikian
et
al
kapikian
et
al
hamparian
et
al
recruit
dr
j
owen
hendley
join
work
avail
viral
serotyp
earlier
attempt
made
trace
spread
individu
viru
type
insur
compani
popul
becam
clear
differ
strain
typic
spread
among
peopl
work
togeth
area
offic
suggest
employe
becom
infect
home
result
turn
attent
rhinoviru
spread
among
famili
employe
home
hendley
et
al
work
led
find
children
usual
first
develop
rhinoviru
cold
famili
result
exposur
school
sick
child
transmit
infect
famili
member
also
serolog
find
studi
combin
data
studi
experiment
infect
volunt
reveal
level
neutral
antibodi
necessari
protect
infect
follow
natur
exposur
hendley
et
al
clear
certain
yet
undetermin
condit
home
promot
spread
rhinoviru
famili
turn
attent
tri
understand
condit
first
evid
bear
rhinoviru
transmiss
came
serendip
conduct
earlier
studi
appear
nasal
mucosa
infect
uninfect
subject
use
dissect
microscop
view
nose
observ
infect
accident
spread
control
subject
way
contamin
nasal
specula
focus
attent
possibl
mechan
accident
introduct
viru
directli
nose
type
intim
activ
take
place
among
famili
member
discov
cold
patient
rhinoviru
nasal
secret
also
frequent
viru
finger
hendley
et
al
patient
sneez
cough
onto
petri
dish
contain
viral
collect
broth
cultur
viru
infrequ
recov
direct
attent
away
viral
spread
larg
small
particl
aerosol
import
contamin
hand
conduct
experi
subject
hand
intent
contamin
rhinoviru
follow
observ
viru
could
effici
transfer
hand
subject
brief
handtohand
contact
rhinoviru
skin
finger
shown
readili
transfer
mucou
membran
nose
eye
mean
finger
contact
site
rhinoviru
also
found
surviv
well
human
skin
environment
surfac
final
number
fingertonos
fingertoey
contact
occur
natur
routin
activ
medic
grand
round
sunday
school
class
record
elabor
set
experi
plan
explor
feasibl
handcontactselfinocul
rout
rhinoviru
transmiss
work
subject
donor
experiment
infect
rhinoviru
expos
suscept
volunt
recipi
one
three
type
exposur
first
type
exposur
donor
recipi
brief
handtohand
contact
follow
donor
touch
nasal
conjunctiv
mucosa
second
type
exposur
recipi
expos
donor
across
small
tabl
donor
cough
talk
loudli
sang
effort
creat
larg
particl
aerosol
third
type
exposur
donor
recipi
hous
continu
day
room
separ
doubl
wire
partit
allow
transmiss
small
particl
aerosol
throughout
room
eleven
none
recipi
respect
type
exposur
becam
infect
find
demonstr
control
condit
experi
small
larg
particl
aerosol
consider
less
effici
spread
rhinoviru
exposur
handcontactselfinocul
rout
hand
contact
implic
possibl
rout
rhinoviru
transmiss
prevent
becam
next
issu
interest
studi
conduct
rhinoviru
appli
subject
hand
hand
treat
varieti
differ
type
commonli
use
steril
agent
wash
hand
soap
water
found
effect
remov
rhinoviru
howev
chemic
agent
test
provid
desir
longlast
virucid
activ
skin
solut
low
concentr
element
iodin
found
effect
abl
keep
hand
steril
h
carter
et
al
use
iodin
hand
treatment
method
prevent
control
blind
contact
prophylaxi
studi
done
mother
famili
instruct
use
iodin
treat
hand
regular
basi
famili
member
recogn
new
cold
hendley
gwaltney
control
group
mother
treat
hand
solut
contain
brown
food
dye
small
nonvirucid
amount
iodin
approxim
famili
studi
year
four
mother
iodin
hand
treatment
group
compar
placebo
group
develop
cold
exposur
index
case
common
cold
none
iodin
treat
patient
compar
placebo
patient
becam
infect
rhinoviru
type
introduc
home
index
case
interrupt
viral
transmiss
treat
hand
demonstr
hand
contactselfinocul
rout
rhinoviru
transmiss
feasibl
occur
natur
condit
thu
appear
accident
rhinoviru
introduct
nose
could
prevent
hand
wash
avoid
fingertonos
fingertoey
contact
probabl
practic
valu
avoid
cold
also
began
studi
pathogenesi
rhinoviru
cold
turner
gwaltney
well
known
rhinoviru
result
obviou
cytopath
effect
cell
cell
cultur
assum
similar
chang
occur
human
nasal
mucosa
person
cold
although
pathogen
event
human
receiv
littl
attent
dr
gordon
dougla
made
import
discoveri
amount
rhinoviru
requir
infect
human
small
one
human
infecti
dose
rhinoviru
could
littl
one
tissu
cultur
infecti
dose
dougla
couch
anoth
import
find
emerg
rhinoviru
challeng
experi
charlottesvil
elsewher
suscept
antibodyfre
peopl
nose
virtual
protect
viru
deposit
nasal
mucosa
exampl
charlottesvil
infect
occur
antibodyfre
subject
challeng
intranas
rhinoviru
interest
infect
subject
develop
symptom
cold
similar
rate
inappar
infect
observ
natur
rhinoviru
infect
gwaltney
work
rhinoviru
pathogenesi
progress
determin
initi
step
viru
introduct
nose
eye
goe
lacrim
duct
nose
follow
transport
viru
posterior
pharynx
adenoid
ciliari
epithelium
nasal
mucu
membran
winther
et
al
dr
birgit
winther
join
charlottesvil
group
dr
niel
mygind
copenhagen
lead
investig
work
infect
appear
initi
posterior
pharynx
lymphoepitheli
cell
present
crypt
adenoid
tissu
cell
shown
rich
major
cellular
receptor
rhinoviru
winther
et
al
anoth
experi
design
investig
time
sequenc
rhinoviru
infect
product
new
viru
upper
airway
shown
occur
rapidli
viral
inocul
nose
new
viru
recogn
within
h
intranas
inocul
harri
gwaltney
symptom
also
observ
begin
earli
within
h
viral
inocul
find
indic
achiev
optimum
benefit
treatment
rhinoviru
cold
dose
start
earli
possibl
onset
symptom
recogn
affect
person
recent
work
dr
eurico
arruda
associ
shown
person
accur
determin
contract
cold
within
h
first
symptom
appear
arruda
et
al
anoth
import
find
emerg
pathogenesi
studi
charlottesvil
unlik
cell
cultur
rhinoviru
caus
signific
amount
cytopatholog
cell
nasal
mucosa
winther
et
al
examin
nasal
biopsi
show
difficult
imposs
detect
histolog
chang
nasal
mucosa
taken
subject
rhinoviru
cold
find
suggest
pathogenesi
rhinoviru
cold
larg
part
associ
activ
variou
inflammatori
event
immun
system
infect
person
past
decad
role
inflammatori
mediat
pathogenesi
rhinoviru
cold
receiv
increas
attent
investig
approach
problem
includ
measur
mediat
nasal
fluid
person
cold
observ
occurr
differ
cold
symptom
volunt
intranas
challeng
known
inflammatori
compound
attempt
blockad
symptom
infect
subject
use
antiinflammatori
compound
known
mechan
action
work
led
discoveri
multipl
inflammatori
event
may
role
rhinoviru
pathogenesi
gwaltney
rueckert
includ
inflammatori
mechan
associ
releas
histamin
kinin
prostaglandin
interleukin
activ
parasympathet
nervou
system
tradit
treatment
cold
direct
symptom
manag
obvious
work
block
inflammatori
pathway
recogn
alpha
adrenerg
activ
oral
topic
decongest
shrink
mucos
swell
nasal
turbin
caus
nasal
obstruct
first
gener
antihistamin
work
block
anticholinerg
activ
reduc
seromuc
gland
secret
contribut
rhinorrhea
suppress
sneez
reflex
turner
et
al
gwaltney
druce
latter
effect
possibl
occur
central
locat
muether
gwaltney
nonsteroid
antiinflammatori
drug
reduc
sore
throat
suppress
cough
sperber
et
al
insel
nozhat
et
al
fogari
et
al
reduc
system
complaint
malais
suppress
effect
cough
may
due
antiprostaglandin
activ
sinc
prostaglandin
potent
stimul
cough
doyl
et
al
discoveri
compound
antivir
activ
rhinoviru
provid
basic
approach
treat
cold
fortun
recruit
dr
frederick
hayden
join
charlottesvil
group
dr
hayden
particular
interest
antivir
compound
treat
respiratori
infect
other
test
sever
compound
human
go
back
unpublish
clinic
trial
conduct
smithklin
french
laboratori
triazinoindol
compound
gwaltney
gwaltney
turner
et
al
howev
result
clinic
trial
disappoint
modest
therapeut
effect
antivir
provid
reason
recogn
role
inflammatori
event
pathogenesi
rhinoviru
cold
turn
attent
cold
treatment
combin
antivir
compound
one
antiinflammatori
compound
approach
show
promis
proof
concept
studi
current
major
interest
gwaltney
trial
recent
complet
rhinoviru
challeng
model
use
combin
treatment
compos
intranas
interferon
plu
oral
chlorpheniramin
ibuprofen
gwaltney
et
al
submit
public
combin
effect
lower
sever
total
individu
symptom
score
reduc
amount
nasal
mucu
product
nasal
tissu
use
short
cours
intranas
interferon
use
treatment
avoid
nasal
irrit
occur
prolong
interferon
administr
work
anoth
area
rhinoviru
pathogenesi
demonstr
sinu
ct
examin
abnorm
paranas
sinus
result
collect
thick
adhes
exud
occur
high
proport
patient
cold
gwaltney
et
al
show
cold
viral
rhinosinus
viral
rhiniti
recent
followup
studi
find
shown
nose
blow
propel
nasal
fluid
middl
meatu
sinus
probabl
account
least
part
sinu
abnorm
observ
cold
gwaltney
et
al
prevent
remov
viscou
adhes
materi
collect
sinu
cold
area
current
interest
look
back
career
span
discoveri
rhinoviru
elucid
epidemiolog
begin
attempt
understand
pathogenesi
solut
atom
structur
rossmann
associ
rossmann
et
al
therapeut
approach
antivir
combin
cold
treatment
excit
stori
follow
privileg
work
field
incept
time
reach
matur
mean
impli
stori
work
field
continu
small
talent
dedic
group
investig
mani
also
person
friend
advantag
small
famili
investig
activ
ad
find
review
believ
long
answer
given
tiresom
old
question
ca
nt
cure
common
cold
answer
chang
epidemiolog
rsv
larri
anderson
center
diseas
control
atlanta
ga
respiratori
syncyti
viru
rsv
long
consid
import
caus
seriou
lower
respiratori
tract
diseas
infant
young
children
throughout
world
import
target
vaccin
develop
last
decad
also
becom
clear
rsv
also
import
pathogen
age
group
think
treatment
prevent
need
includ
infant
young
child
compromis
cardiac
immun
respiratori
system
age
elderli
unfortun
effort
develop
rsv
vaccin
yet
success
sporad
prevent
rsv
diseas
limit
current
rsv
immun
globulin
human
murin
monoclon
antibodi
prophylaxi
seriou
rsv
diseas
prematur
infant
infant
chronic
lung
diseas
us
rsv
caus
yearli
outbreak
usual
begin
late
fall
winter
last
late
winter
spring
outbreak
occur
commun
region
nation
outbreak
illustr
variat
time
outbreak
commun
differ
outbreak
strain
commun
rsv
outbreak
consist
associ
substanti
increas
hospit
bronchiol
pneumonia
children
b
year
age
use
nation
hospit
discharg
diagnosi
data
death
certif
data
estim
rsv
associ
bronchiol
pneumonia
hospit
death
children
year
age
year
commun
rsv
outbreak
also
bring
risk
nosocomi
outbreak
substanti
concern
hospit
person
age
especi
patient
compromis
immun
system
recipi
bone
marrow
transplant
report
mortal
rate
rsv
pneumonia
molecular
epidemiolog
studi
demonstr
rsv
nosocomi
outbreak
often
result
multipl
introduct
distinct
strain
commun
last
decad
import
rsv
caus
seriou
lower
respiratori
infect
lri
elderli
patient
becom
increasingli
appreci
studi
commun
acquir
lri
year
age
ohio
suggest
rsv
associ
lri
hospit
rsv
outbreak
season
age
appli
rate
rsv
detect
prospect
studi
lri
adult
nation
hospit
discharg
diagnosi
death
certif
data
estim
rsv
lead
hospit
death
year
us
person
year
age
unpublish
data
obtain
similar
result
rsvassoci
death
us
model
use
viru
detect
surveil
data
multipl
caus
death
data
estim
rsv
influenzaassoci
death
model
suggest
rsv
may
caus
number
death
influenza
recent
studi
use
improv
diagnost
method
ie
rtpcr
support
concept
rsv
caus
amount
diseas
influenza
adult
patient
zambon
et
al
studi
rsv
detect
rate
e
rate
influenza
detect
patient
influenzalik
ill
one
limit
defin
epidemiolog
rsv
diseas
older
children
adult
abil
detect
infect
serolog
sensit
method
detect
rsv
infect
older
children
adult
viru
isol
antigen
detect
assay
like
detect
infect
recent
develop
nest
sensit
pcrbase
assay
howev
appear
give
sensit
closer
compar
serolog
studi
make
possibl
character
epidemiolog
rsv
diseas
elderli
popul
recent
appli
pcr
studi
lri
infant
young
children
found
pcr
may
markedli
improv
rsv
diagnosi
popul
well
studi
nearli
doubl
number
rsv
posit
specimen
sensit
pcr
assay
compar
tissu
cultur
isol
studi
acut
otiti
media
tapani
nation
public
health
institut
helsinki
finland
associ
picornavirus
rhinovirus
enterovirus
acut
otiti
media
aom
known
long
time
recent
studi
demonstr
virus
associ
half
case
young
children
aom
last
sever
year
nation
public
health
institut
ktl
helsinki
finland
particip
two
larg
prospect
studi
aom
children
younger
year
first
studi
finom
cohort
studi
one
primari
question
see
differ
viral
infect
differ
role
risk
factor
aom
whenev
children
respiratori
symptom
sampl
viru
studi
collect
second
studi
finom
vaccin
studi
children
receiv
either
pneumococc
conjug
hepat
b
vaccin
sampl
collect
limit
event
studi
physician
diagnos
aom
child
sampl
collect
includ
nasopharyng
aspir
middl
ear
fluid
mef
aom
addit
pair
sera
cohort
studi
cohort
studi
rhinovirus
frequent
encount
virus
patient
aom
rhinovirus
rsv
parainfluenza
influenza
adenovirus
influenza
b
parainfluenza
found
associ
aom
episod
frequenc
influenza
b
parainfluenza
extrem
low
enterovirus
screen
vesa
et
al
rhinovirus
detect
combin
cell
cultur
rtpcr
method
wherea
antigen
detect
use
virus
mani
infect
miss
latter
techniqu
subgroup
aom
episod
studi
serolog
reveal
significantli
case
et
al
unpublish
second
studi
enterovirus
also
screen
direct
rtpcr
common
second
rhinovirus
togeth
rhinovirus
enterovirus
associ
aom
episod
noksokoivisto
et
al
unpublish
studi
rhinoviru
serotyp
prompt
epidemiolog
analysi
finom
cohort
studi
studi
found
strong
correl
hrv
infect
nasopharynx
hrv
isol
mef
two
epidem
viru
found
rel
frequent
ear
rais
question
possibl
specif
ototrop
strain
question
difficult
answer
convent
serotyp
hrv
extrem
tediou
studi
good
collect
repres
viru
strain
differ
season
rtpcr
amplicon
sequencingbas
method
rhinoviru
identif
similar
recent
establish
enterovirus
explor
approach
target
two
genom
region
nt
motif
code
part
code
region
region
initi
chosen
rel
easi
get
work
primer
work
develop
primer
code
region
enterovirus
reliabl
serotyp
identif
region
ongo
use
phylogenet
analysi
base
sequenc
hrv
prototyp
strain
cluster
two
known
group
human
rhinovirus
hrv
b
except
one
except
appear
closer
rel
enteroviru
rhinovirus
gener
prototyp
strain
easili
distinguish
although
six
pair
serotyp
rel
close
includ
current
unnumb
hank
strain
close
sixtyon
field
isol
collect
finom
cohort
studi
also
includ
analysi
use
rang
evolutionari
differ
prototyp
strain
criterion
serotyp
mani
differ
serotyp
might
circul
among
children
singl
suburb
tamper
autumn
spring
one
may
new
serotyp
closebi
prototyp
strain
known
serotyp
savolainen
et
al
press
detail
studi
conduct
sequenc
region
even
closer
hev
member
appear
prime
strain
neutral
capabl
induc
crossneutr
two
virus
definit
acidsensit
strain
appear
exploit
daf
receptor
helaohio
cell
blomquist
et
al
virus
sequenc
two
substrain
three
region
region
strain
close
clearli
hev
substrain
cluster
togeth
also
similar
region
noncod
region
two
virus
clearli
distinct
known
cluster
togeth
hev
c
poliovirus
region
hev
hev
b
form
anoth
group
two
cluster
hrv
branch
studi
clear
one
hrv
prototyp
strain
repres
establish
serotyp
cluster
two
known
genet
group
hrv
hrv
b
n
respect
except
appear
share
serotyp
ident
ev
member
hevd
cluster
differ
acid
labil
like
true
rhinovirus
uniqu
ncr
sequenc
share
receptor
specif
daf
hela
cell
prospect
genet
identifi
hrv
strain
appear
promis
requir
technic
improv
sequenc
studi
new
unclassifi
hrv
serotyp
may
discov
updat
influenza
ann
reid
arm
forc
institut
patholog
md
infam
spanish
influenza
origin
spring
although
initi
wave
infect
lethal
us
late
spring
earli
summer
viru
spread
europ
second
wave
start
end
august
contin
explod
worldwid
pandem
septemb
novemb
pandem
kill
million
peopl
worldwid
us
alon
viru
struck
particularli
strong
blow
us
troop
respons
american
death
entir
war
viru
power
enough
caus
transient
approxim
reduct
averag
life
expect
us
viru
behav
differ
studi
strain
caus
signific
number
death
young
adult
peak
age
addit
caus
increas
morbid
mortal
among
young
old
better
understand
pathogenesi
behind
sever
infect
essenti
analyz
viru
recoveri
viral
rna
autopsi
specimen
patient
die
pandem
secondari
acut
viral
pneumonia
seventyf
sampl
found
case
evid
pcr
viru
rna
first
patient
privat
ft
jackson
sc
die
septemb
sick
day
influenza
pneumonia
second
patient
privat
camp
upton
ny
die
septemb
sick
day
influenza
pulmonari
edema
third
case
eventu
identifi
inuit
woman
exhum
teller
mission
brevig
mission
ak
die
villag
novemb
adult
inhabit
die
within
week
secondari
influenza
ill
less
day
prior
die
lung
sampl
rna
first
extract
revers
transcrib
cdna
small
fragment
amplifi
pcr
clone
sequenc
sequenc
final
confirm
compar
known
influenza
strain
sequenc
scientist
hope
understand
viru
came
first
infect
man
viru
lethal
genet
featur
relat
virul
behavior
activ
host
respons
date
gene
segment
surfac
glycoprotein
hemagglutinin
neuraminidas
intern
protein
nonstructur
matrix
nucleoprotein
sequenc
reid
et
al
reid
et
al
basler
et
al
three
polymeras
gene
still
sequenc
sequenc
analysi
indic
hemagglutinin
ha
cleavag
site
mutat
seen
hong
kong
virul
poultri
influenza
strain
ha
receptor
bind
pattern
consist
avian
origin
minim
mammalian
adapt
antigen
site
ha
match
avian
consensu
phylogenet
analys
place
ha
solidli
within
near
root
mammalian
clade
make
avianlik
mammalian
sequenc
phylogenet
analysi
place
ha
sequenc
near
intersect
human
swine
influenza
plot
rate
amino
acid
chang
year
ha
clear
strain
lie
close
predict
intersect
human
swine
ha
analysi
neuraminidas
na
show
consist
result
observ
ha
ha
na
gene
almost
certainli
differ
previous
circul
strain
circul
wide
human
popul
pandem
focu
turn
intern
protein
gene
better
understand
viru
matrix
sequenc
found
contain
nucleotid
segment
consensu
open
read
frame
mutat
known
affect
virul
found
transmembran
domain
show
sequenc
would
confer
amantadin
resist
phylogenet
matrix
sequenc
near
root
human
swine
clade
extracellular
domain
speciesspecif
motif
unknown
function
signific
use
better
understand
sourc
viru
sequenc
match
subsequ
human
strain
consist
retain
previou
circul
human
strain
sequenc
differ
one
amino
acid
human
sequenc
extracellular
domain
collabor
research
st
bartholomew
royal
london
hospit
group
arm
forc
institut
patholog
result
identif
addit
case
london
influenza
rna
present
rtpcr
preserv
tissu
signal
three
case
weak
detail
analysi
predomin
conduct
stronger
signal
sequenc
two
case
ident
abrevig
viru
thu
confirm
rel
genet
uniform
pandem
viru
sinc
influenza
viru
appear
avian
origin
attent
turn
identifi
specimen
wild
waterfowl
help
dick
slemon
jame
dean
wild
waterfowl
repres
speci
collect
catalogu
preserv
ethanol
identifi
smithsonian
institut
washington
dc
cloacal
biopsi
cloacal
lavag
larg
intestin
biopsi
perform
bird
six
bird
posit
influenza
rna
rtpcr
domain
consensu
primer
use
screen
subtyp
brant
goos
branta
bernicla
collect
g
hanna
septemb
pribilof
island
ak
posit
influenza
viru
abrant
viru
partial
sequenc
includ
nucleotid
domain
nucleotid
nucleoprotein
np
nucleotid
matrix
gene
preliminari
data
appear
antigen
site
residu
match
avian
consensu
site
involv
receptor
bind
site
phylogenet
np
near
root
north
american
avian
clade
current
think
signific
drift
wild
avian
influenza
virus
year
pandem
strain
phylogenet
distinct
avian
clade
unlik
strain
appar
acquir
ha
directli
bird
strain
evolv
time
mammalian
host
na
also
chang
avian
sequenc
na
intern
protein
gene
may
may
reassort
although
ns
np
gene
sequenc
consist
retent
previous
circul
human
strain
studi
avian
influenza
virus
circul
around
time
pandem
well
human
influenza
virus
need
fulli
understand
recent
isol
viru
newli
human
caus
respiratori
diseas
albert
osterhau
erasmu
rotterdam
netherland
new
viru
human
metapneumoviru
hmpv
recent
character
van
den
hoogen
et
al
search
viru
began
sever
children
present
histori
rsvlike
acut
respiratori
ill
neg
rsv
test
result
cell
cultur
show
agent
slow
replic
tmk
cell
poor
growth
vero
cell
mdck
cef
cell
appear
support
replic
replic
trypsindepend
rsvlike
cytopath
effect
could
seen
day
incub
paramyxoviruslik
particl
seen
electron
micrograph
hemagglutin
turkey
chicken
guinea
pig
erythrocyt
could
demonstr
result
particl
screen
random
prime
polymeras
chain
reaction
pcr
clone
sequenc
viru
ten
clone
recov
indic
viru
similar
genet
organ
avian
pneumovirus
sequenc
first
viru
complet
evid
new
viru
differ
avian
pneumoviru
viru
would
replic
chicken
inocul
macaqu
two
four
macaqu
mild
respiratori
symptom
predomin
rhiniti
microscop
examin
respiratori
tissu
found
viral
infect
nose
lung
alveoli
day
infect
base
find
new
viru
name
hmpv
next
serolog
studi
children
show
antibodi
hmpv
highli
preval
year
age
children
investig
seroposit
collect
sera
origin
taken
test
immunofluoresc
viru
neutral
assay
antibodi
found
sera
test
clinic
data
sampl
collect
prospect
winter
season
suggest
hmpv
associ
respiratori
tract
ill
particularli
young
children
winter
season
predomin
symptom
similar
caus
rsv
rang
ill
mild
respiratori
symptom
sever
bronchiol
pneumonia
ten
percent
children
respiratori
tract
ill
screen
season
hmpv
isol
without
evid
coinfect
respiratori
pathogen
human
mpv
vrna
could
detect
throat
swab
healthi
children
two
genet
cluster
hmpv
isol
found
netherland
may
repres
differ
serotyp
hmpv
cluster
viru
like
worldwid
distribut
may
signific
impact
young
old
addit
patient
compromis
immun
underli
medic
condit
date
antivir
suscept
test
evalu
viru
guy
citi
hmpv
newli
describ
paramyxovirida
genotyp
distinct
pneumovirus
anim
metapneumovirus
recent
detail
descript
epidemiolog
limit
netherland
van
den
hoogen
et
al
decid
verifi
presenc
hmpv
canada
describ
clinic
spectrum
thirtynin
specimen
evid
cytopath
effect
cell
mdck
hff
vero
mink
lung
rd
cell
fail
hemabsorb
human
rbc
neg
rtpcr
influenza
b
rsv
adenoviru
parainfluenza
viru
measl
mump
grown
respiratori
sampl
patient
cytopath
effect
evid
mean
incub
time
day
rang
day
one
isol
show
evid
coinfect
measl
rapid
antigen
test
sampl
posit
concurr
influenza
b
rsv
thirtyeight
thirtynin
isol
subject
posit
rtpcr
hmpv
f
gene
analysi
f
protein
reveal
similar
amino
acid
level
phylogenet
analysi
reveal
one
virus
cluster
one
two
major
group
electron
microscopi
reveal
pleomorph
spheric
filament
particl
consist
paramyxovirus
clinic
patient
hospit
febril
respiratori
condit
live
longterm
care
facil
seen
privat
clinic
eightyseven
percent
sampl
collect
decemb
may
mean
age
rang
year
patient
younger
year
old
older
year
old
detail
clinic
find
obtain
patient
third
youngest
patient
underli
condit
present
fever
tachypnea
dyspnea
cough
wheez
patient
hospit
three
admit
icu
requir
mechan
ventil
one
patient
die
pneumon
ard
without
anoth
identifi
pathogen
older
patient
underli
condit
present
cough
fever
tachypnea
dyspnea
six
elderli
requir
hospit
nurs
home
requir
icu
stay
patient
middl
rang
typic
present
fever
cough
tachypnea
dyspnea
sore
throat
twothird
underli
condit
immunocompromis
patient
requir
hospit
one
mechan
ventil
icu
clear
hmpv
similar
viru
describ
europ
circul
canada
hmpv
present
nonspecif
viral
respiratori
ill
vri
typic
extrem
age
peopl
underli
medic
condit
abl
caus
wide
rang
ill
includ
mild
upper
respiratori
symptom
sever
lower
respiratori
tract
diseas
thirtytwo
year
antigen
genet
influenza
derek
smith
erasmu
rotterdam
netherland
hemagglutin
inhibit
hi
assay
typic
consid
low
resolut
capabl
reliabl
discrimin
antigen
least
differ
hi
titer
resolut
suffici
tell
differ
major
drift
variant
suffici
judg
finer
differ
new
mathemat
method
use
make
antigen
map
hi
data
develop
new
method
increas
resolut
hi
interpret
also
provid
visual
antigen
relationship
among
mani
antigen
merg
exist
hi
tabl
hi
tabl
span
contain
antigen
strain
sera
creat
antigen
map
creat
merg
tabl
show
pattern
antigen
evolut
last
year
mapmak
method
also
appli
genet
data
produc
visual
genet
evolut
antigen
merg
hi
data
tabl
allow
comparison
antigen
genet
evolut
influenza
techniqu
offer
new
method
monitor
antigen
chang
evolut
among
influenza
virus
diagnosi
respiratori
viral
infect
complic
overlap
clinic
spectra
infect
multipl
detect
method
variabl
sensit
specif
past
year
diagnost
techniqu
refin
improv
result
militari
research
space
explor
requir
miniatur
drive
toward
overthecount
sale
treatment
diagnost
improv
result
reduct
time
report
posit
result
well
week
hour
current
avail
method
detect
old
novel
virus
includ
cultur
immunofluoresc
near
patient
test
npt
pcr
serolog
test
strength
weak
provid
use
role
overal
diagnost
strategi
perhap
greatest
improv
diagnost
widespread
avail
pcr
pcr
improv
detect
viru
aid
infect
control
assist
appropri
prescrib
unfortun
expens
techniqu
also
result
less
cultur
viru
result
loss
antigen
inform
avail
viabl
viru
sever
recent
studi
shown
much
higher
rate
detect
respiratori
virus
pcr
compar
cultur
stockton
et
al
carman
et
al
fan
et
al
parallel
test
done
multiplex
method
effici
detect
respiratori
virus
rather
sequenti
serial
test
individu
virus
ultim
lab
run
sever
differ
multiplex
test
complet
respiratori
viru
screen
pcr
technolog
also
allow
quantit
viru
van
elden
et
al
well
studi
molecular
epidemiolog
increas
sensit
diagnosi
particularli
import
adult
shed
less
viru
eg
rsv
earli
infect
may
also
assist
surveil
zambon
et
al
result
improv
surveil
sensit
molecular
diagnosi
becom
clear
differ
respiratori
virus
may
cocircul
occas
acut
respiratori
infect
peak
winter
season
caus
one
pathogen
dual
infect
clinic
implic
cocircul
still
investig
use
quantit
realtim
pcr
infanc
respiratori
virus
first
public
appear
influenza
although
opportun
offer
rapid
diagnost
excit
remain
sever
issu
requir
research
includ
sensit
realtim
pcr
test
respiratori
sampl
come
commun
adult
overal
viral
load
low
practic
difficulti
select
suitabl
detect
combin
multiplex
analysi
avoid
substanti
parallel
test
find
way
adapt
chemistri
real
time
pcr
allow
analysi
product
eg
sequenc
rflp
also
clear
molecular
approach
essenti
detect
novel
pathogen
best
demonstr
recent
descript
hmpv
human
mpv
first
describ
use
random
access
pcr
approach
test
clinic
sampl
subsequ
refin
primer
set
use
diagnosi
van
den
hoogen
et
al
newli
develop
pcr
test
use
look
commun
respiratori
sampl
collect
influenza
season
screen
hmpv
england
season
mild
influenza
season
hmpv
detect
influenzalikeil
ili
patient
neg
influenza
rsv
england
analysi
clinic
featur
case
appear
viru
present
nonspecif
respiratori
viral
infect
peak
incid
decemb
viru
affect
sex
age
group
age
particularli
common
elderli
patient
receiv
year
influenza
vaccin
molecular
archaeolog
involv
pcr
amplif
nucleic
acid
archiv
tissu
specimen
power
investig
tool
approach
also
use
detect
influenza
pandem
allow
investig
virus
circul
time
reid
et
al
past
shown
incid
sudden
infant
death
syndrom
correl
close
incid
acut
respiratori
diseas
commun
preserv
specimen
sid
case
appropri
patholog
syndrom
screen
respiratori
virus
anoth
major
advanc
diagnosi
came
form
officebas
diagnost
npt
diagnost
kit
vari
complex
well
sensit
specif
quidel
quickview
dipstick
influenza
test
analys
vitro
vivo
experiment
viru
dilut
seri
rapid
diagnost
test
lower
limit
detect
dilut
use
antigen
detect
wherea
kit
much
sensit
nucleic
acid
elut
strip
pcr
use
detect
viral
genom
field
studi
rapid
diagnost
also
perform
less
well
manufactur
result
sensit
vs
sensit
vs
pcr
vs
cultur
taken
togeth
two
result
indic
sensit
limit
current
technolog
antigen
antibodi
complex
simpl
method
involv
detect
nucleic
acid
may
requir
deliv
kind
sensit
specif
requir
test
truli
use
individu
patient
manag
along
line
method
stabil
rna
guanidinium
transport
media
swab
streak
onto
filter
paper
imbed
antidegrad
compound
enhanc
detect
viral
genom
clinic
sampl
pcr
enabl
easier
broadli
base
sampl
note
method
destroy
viru
infect
would
requir
collect
second
sampl
cultur
serolog
diagnosi
respiratori
virus
depend
detect
antibodi
blood
use
hemagglutin
inhibit
test
hi
test
influenza
virus
howev
increas
interest
detect
antibodi
bodi
fluid
particularli
effort
find
noninvas
method
sampl
altern
correl
immun
protect
vaccin
trial
particularli
relev
field
respiratori
viral
vaccin
mucos
deliveri
vaccin
import
approach
therefor
appropri
consid
use
oral
fluid
sourc
antibodi
develop
altern
form
antibodi
test
sever
collect
method
may
improv
abil
collect
gingiv
transud
noke
et
al
method
valid
acut
diagnosi
parvoviru
hiv
hepatitisviru
infect
well
assess
immun
antibodi
level
measl
mump
rubella
vaccin
array
technolog
macronucleotid
micronucleotid
oligonucleotid
chip
emerg
techniqu
futur
allow
diagnosi
infect
well
correl
diseas
pathogenesi
host
respons
gene
capac
look
broad
array
gene
also
allow
identif
genet
divers
genet
technolog
also
use
part
sequenc
databas
done
influenza
databas
describ
elsewher
articl
final
emerg
techniqu
use
health
forecast
unit
dobson
note
chang
weather
correl
health
care
util
increas
mortal
donaldson
keating
result
unit
set
england
forecast
probabl
admiss
best
guid
use
resourc
base
meteorolog
data
unit
collect
maximum
minimum
temperatur
well
weather
pattern
daili
postcod
socioeconom
data
postcod
virolog
surveil
data
clinic
morbid
hospit
episod
statist
post
code
age
length
stay
diagnosi
produc
predict
regard
probabl
hospitalis
allow
optimum
use
health
resourc
examin
pattern
occurr
influenza
pandem
last
year
indic
import
china
sourc
focus
southern
china
recent
year
potter
inform
contribut
hypothesi
southern
china
epicent
emerg
influenza
pandem
shortridg
stuartharri
hypothesi
trace
origin
back
domest
duck
china
around
bc
domest
duck
brought
influenza
virus
farmyard
potenti
opportun
infect
human
role
domest
anim
pig
introduc
nonhuman
influenza
virus
human
popul
also
appear
like
scholtissek
et
al
pandem
influenza
zoonosi
domest
anim
like
immedi
sourc
viru
shortridg
understand
southern
china
potenti
sourc
futur
pandem
provid
state
awar
influenza
viru
recogn
chicken
human
hong
kong
subbarao
et
al
claa
et
al
yuen
et
al
chicken
recogn
sourc
viru
human
influenza
viru
infect
chicken
uncommonli
recogn
hong
kong
around
detect
viru
shortridg
chicken
outbreak
act
amplifi
host
viru
incid
stop
slaughter
poultri
across
hong
kong
sar
pandem
believ
avert
term
avert
use
sinc
known
highli
pathogen
viru
occur
elsewher
region
virus
may
precursor
last
human
case
recogn
day
slaughter
commenc
matter
specul
whether
would
human
case
poultri
slaughter
reintroduct
poultri
market
began
earli
time
duck
gees
among
aquat
poultri
allow
singl
segreg
wholesal
market
segreg
put
place
minim
spread
virus
landbas
poultri
sold
live
retail
market
throughout
sar
shortridg
guan
et
al
intens
surveil
poultri
market
antigen
genet
analys
isol
obtain
surveil
studi
incid
indic
differ
viru
precursor
host
involv
genesi
highli
pathogen
viru
xu
et
al
guan
et
al
hoffmann
et
al
precursor
viru
gees
ie
goos
gogd
acquir
replic
complex
quail
viru
viru
also
quail
provid
n
gene
encod
na
characterist
amino
acid
delet
stalk
inform
engend
precautionari
principl
enabl
hong
kong
monitor
poultri
variou
set
order
limit
risk
viru
reemerg
regener
local
econom
threat
poultri
industri
importantli
potenti
global
health
threat
human
shortridg
anoth
potenti
danger
viru
recogn
hong
kong
may
gogd
viru
isol
gees
detect
duck
later
viru
found
undergon
reassort
unknown
avian
influenza
viru
waterfowl
infect
duck
gees
wholesal
market
april
five
genotyp
precursor
gogd
isol
appar
healthi
chicken
retail
market
genet
ground
predict
would
highli
pathogen
chicken
confirm
experiment
pathogen
studi
rg
webster
person
commun
address
impend
threat
govern
expert
work
group
met
develop
unifi
strategi
deal
market
media
public
relat
event
chicken
die
retail
market
inde
midmay
chicken
infect
go
gd
genotyp
began
die
soon
decis
made
slaughter
poultri
across
sar
except
chicken
certain
farm
new
territori
defin
age
decis
taken
minim
risk
five
genotyp
chicken
reassort
virus
present
quail
live
retail
market
produc
virul
viru
slaughter
carri
phase
oper
human
case
recogn
introduct
rest
day
month
poultri
market
must
sold
kill
market
thoroughli
cleans
disinfect
step
toward
prevent
amplif
virus
market
event
gogdlik
viru
might
still
gain
entri
retail
market
plan
withdraw
quail
host
virus
market
seen
risk
minim
step
gener
viru
hong
kong
influenza
sentinel
post
wider
region
hong
kong
may
abl
react
quickli
influenza
incid
react
area
beyond
geograph
confin
base
surveil
studi
poultri
viral
gene
host
still
present
immedi
area
could
allow
viru
reappear
altern
reassort
appear
five
gogd
virus
probabl
repres
intermedi
transit
viru
detect
preemptiv
slaughter
probabl
prevent
progress
virul
human
pathogen
beyond
hypothet
stage
duck
rais
practic
similar
southern
china
carri
mani
part
east
asia
suggest
possibl
viru
could
aris
elsewher
within
wide
region
chicken
viru
could
introduc
new
set
area
cover
heterosubtyp
immun
afford
previou
infect
oneil
et
al
howev
virus
may
occur
region
occurr
gogdlik
viru
viru
characterist
na
poultri
unknown
moreov
unless
gogd
viru
occur
beyond
east
asia
present
hard
imagin
pathogen
form
aris
region
viru
right
caus
concern
gene
replic
complex
similar
viru
guan
et
al
one
lineag
viru
alreadi
isol
two
young
children
influenzalik
ill
hong
kong
peiri
et
al
lin
et
al
anoth
pig
import
hong
kong
viru
recogn
poultri
beyond
east
asia
middl
east
europ
southern
africa
could
caus
concern
insid
outsid
epicent
alexand
cameron
et
al
histori
usual
repeat
insofar
origin
pandem
concern
attent
must
paid
china
particularli
southern
china
earli
detect
futur
pandem
geograph
area
southern
china
origin
pandem
incid
outlin
event
furthermor
circumstanti
evid
origin
pandem
shortridg
prepandem
pandem
viru
smolder
human
nonhuman
host
could
eventu
emerg
east
asia
outsid
epicent
could
indigen
aris
furthermor
given
complex
popul
dynam
human
domest
poultri
recent
time
possibl
next
pandem
could
aris
even
beyond
east
asia
exclud
sever
epidemiolog
studi
link
rhinovirus
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
recent
mechan
rhinoviru
induc
asthma
begun
understood
larg
studi
children
wheez
cough
past
year
children
ask
keep
daili
diari
symptom
see
physician
evalu
asthma
exacerb
upper
lower
respiratori
tract
symptom
score
e
subject
feel
cold
routin
cultur
pcr
rhinovirus
coronavirus
test
collect
sampl
found
respiratori
viru
infect
commonli
hrv
patient
asthma
exacerb
number
recent
studi
confirm
find
rake
et
al
freymuth
et
al
adult
copd
often
develop
exacerb
underli
diseas
infect
rhinovirus
studi
patient
moder
sever
copd
nasal
aspir
andor
nasopharyng
swab
collect
exacerb
pcr
done
common
respiratori
pathogen
serum
collect
inflammatori
marker
thirtynin
percent
exacerb
associ
viru
detect
rhinovirus
viral
exacerb
associ
significantli
increas
dyspnea
higher
total
symptom
score
present
longer
median
durat
symptom
greater
fall
peak
expiratori
flow
rate
higher
plasma
level
fibrinogen
seemung
et
al
crucial
question
pathogenesi
rhinoviru
induc
lower
airway
diseas
whether
viru
directli
infect
respiratori
epithelium
lead
lower
airway
inflamm
inflamm
consequ
neural
reflex
system
immun
respons
infect
restrict
upper
respiratori
tract
clear
viru
replic
success
certain
strain
may
grow
better
bodi
temperatur
would
found
lung
cooler
temperatur
found
upper
respiratori
tract
papadopoulo
et
al
addit
rhinovirus
replic
vitro
primari
bronchial
epitheli
cell
cultur
evidenc
increas
viral
titer
increas
viral
rna
new
viral
protein
synthesi
visibl
cytopath
effect
papadopoulo
et
al
clinic
sampl
experiment
infect
volunt
situ
hybrid
biopsi
specimen
detect
rhinoviru
genom
replic
rna
strand
detect
rate
found
upper
respiratori
tract
sampl
papadopoulo
et
al
infect
cell
vitro
also
caus
releas
proinflammatori
mediat
like
rant
schroth
et
al
papadopoulo
et
al
upregul
cell
surfac
marker
like
major
histocompat
complex
mhc
class
papi
et
al
papi
johnston
papi
johnston
natur
experiment
infect
also
associ
evid
inflamm
shown
increas
mucos
cell
eosinophil
fraenkel
et
al
mucos
mast
cell
macrophag
sputum
eosinophil
cation
protein
grunberg
et
al
grunberg
et
al
also
emerg
evid
leukotrien
level
leukotrien
prostanoid
synthet
enzym
flap
cyclooxygenas
cox
elev
rhinovir
infect
degre
elev
correl
sever
symptom
seymour
et
al
press
final
evid
cellular
damag
elev
level
sputum
ldh
patient
asthma
exacerb
secondari
rsv
influenza
rhinovirus
degre
ldh
elev
also
appear
major
predictor
length
hospit
stay
therefor
like
marker
sever
infect
wark
et
al
press
host
respons
may
play
role
exacerb
way
peripher
blood
mononuclear
cell
asthmat
incub
rhinovirus
vitro
defici
ifng
respons
rel
nonasthmat
suggest
defici
type
immun
respons
may
increas
suscept
asthmat
subject
respiratori
viral
infect
papadopoulo
et
al
press
clinic
studi
asthmat
versu
nonasthmat
alter
immun
respons
appear
increas
frequenc
infect
seem
modul
durat
sever
upper
respiratori
tract
diseas
asthmat
patient
though
sever
prolong
lower
tract
diseas
sever
fall
peak
expiratori
flow
rate
corn
et
al
rhinovirus
thu
major
caus
asthma
copd
exacerb
direct
lower
airway
infect
result
inflamm
appear
major
mechan
exacerb
although
asthmat
may
defici
type
immun
respons
contribut
problem
result
therapi
rhinoviru
induc
lower
respiratori
tract
diseas
ideal
reach
lower
airway
viral
infect
hypothes
predispos
protect
later
develop
asthmat
diseas
well
acut
precipit
asthmat
attack
person
asthma
rsv
particular
interest
relationship
asthmat
diseas
caus
obstruct
airway
diseas
wheez
clinic
similar
asthma
addit
rsv
lower
respiratori
tract
diseas
infanc
associ
childhood
asthmat
diseas
possibl
underli
asthmat
diseas
predispos
rsv
diseas
possibl
rsv
infect
predispos
asthmat
diseas
link
rsv
diseas
asthma
rais
possibl
parallel
pathogenesi
two
diseas
rsv
singl
import
caus
seriou
lower
respiratori
tract
ill
infant
young
children
caus
repeat
infect
throughout
life
associ
seriou
lri
especi
patient
compromis
cardiac
respiratori
immun
system
elderli
similar
clinic
pathogen
featur
rsv
asthmat
diseas
suggest
lesson
learn
one
may
provid
clue
pathogenesi
rsv
neg
strand
rsv
viru
genom
encod
protein
includ
two
surfac
protein
import
induc
protect
immun
fusion
f
protein
put
bind
g
protein
f
protein
effect
induc
protect
immun
g
protein
induc
degre
protect
immun
also
appear
particip
diseas
process
recent
identifi
two
factor
contribut
biolog
rsv
infect
probabl
pathogenesi
diseas
associ
g
protein
two
factor
could
also
particip
pathogenesi
asthmat
diseas
first
rsv
g
protein
contain
chemokin
motif
g
protein
properti
similar
correspond
chemokin
fractalkin
fkn
second
rsv
possibl
g
protein
induc
neurokinin
substanc
p
sp
induct
sp
associ
increas
inflammatori
respons
lung
rsvinfect
mice
rsv
g
protein
fkn
larg
highli
glycosyl
gylcoprotein
contain
intracellular
transmembran
extracellular
domain
heparin
bind
domain
hbd
motif
produc
transmembran
shorter
secret
form
g
protein
also
function
properti
similar
fkn
bind
chemokin
receptor
shown
bind
bind
inhibit
studi
use
cell
transfect
percent
cell
posit
g
protein
bind
increas
cell
transfect
cell
increas
bind
inhibit
g
protein
monoclon
antibodi
fkn
antibodi
g
protein
peptid
contain
motif
g
also
block
fkn
bind
cell
interestingli
rsv
bind
facilit
infect
cell
indic
plaqu
reduct
assay
sinc
rsv
also
use
hbd
infect
cell
first
block
hbd
heparin
heparin
gave
reduct
plaqu
addit
g
protein
g
protein
peptid
motif
peptid
without
motif
fkn
antibodi
increas
reduct
rsv
plaqu
final
g
protein
motif
induc
leukocyt
chemotaxi
fashion
similar
fkn
use
modifi
boyden
chamber
studi
leukocyt
chemotaxi
found
cell
migrat
toward
g
protein
fkn
media
control
fkn
antig
antif
protein
monoclon
antibodi
antibodi
inhibit
cell
migrat
toward
g
addit
clone
express
g
protein
contain
motif
induc
leukocyt
migrat
g
protein
lack
motif
induc
leukocyt
chemotaxi
thu
motif
g
protein
appear
import
biolog
rsv
infect
possibl
pathogenesi
diseas
region
g
protein
could
import
develop
vaccin
antivir
drug
motif
g
may
also
particip
asthmaticlik
aspect
rsv
diseas
suggest
abil
fkn
induc
sp
sp
neurokinin
link
asthmat
diseas
rsv
diseas
sp
amino
acid
tachykinin
rang
effect
includ
induct
vasodil
increas
vascular
permeabl
mucu
secret
induct
immun
inflammatori
respons
rsv
infect
increas
level
sp
bronchial
alveolar
lavag
bal
specimen
mice
addit
sp
immun
activ
lymphocyt
increas
prolifer
inhibit
action
sp
antisp
antibodi
inflammatori
respons
rsv
infect
decreas
particularli
evid
studi
mice
immun
formalininactiv
fi
rsv
vaccin
firsv
immun
mice
mount
enhanc
inflammatori
respons
rsv
challeng
treatment
firsvimmun
mice
antisp
antibodi
block
much
enhanc
inflammatori
respons
exemplifi
decreas
percent
eosinophil
polymorphonuclear
cell
day
post
challeng
bal
sampl
abil
antisp
antibodi
decreas
inflammatori
respons
rsv
infect
suggest
antibodi
might
use
adjunct
antivir
treatment
fact
antivir
drug
neutral
antibodi
monoclon
antibodi
effect
decreas
viral
titer
rel
ineffect
decreas
diseas
rais
possibl
substanti
proport
rsv
diseas
result
virusinduc
immun
inflammatori
respons
steroid
consid
mean
decreas
rsvassoci
inflammatori
respons
steriod
also
delay
viru
clearanc
found
addit
antisp
antibodi
treatment
rsv
neutral
f
protein
antibodi
day
rsv
challeng
markedli
decreas
inflammatori
respons
delay
viru
clearanc
exampl
total
number
cell
decreas
within
one
day
administr
antisp
antibodi
antisp
antibodi
mean
block
sp
activ
could
effect
adjunct
antirsv
drug
immun
therapi
immunopathogenesi
rsv
diseas
peter
openshaw
imperi
colleg
scienc
technolog
medicin
london
uk
although
immun
respons
viru
infect
usual
protect
also
harm
induc
strong
immun
respons
essenti
aim
vaccin
risk
diseas
enhanc
infantil
bronchiol
sever
diseas
typic
develop
sever
day
appar
onset
infect
time
viral
titr
low
fall
inflammatori
respons
peak
anim
model
strongli
suggest
vaccin
enhanc
rsv
diseas
may
due
strong
perhap
unbalanc
cell
prime
although
infectionenhanc
antibodi
may
also
play
role
enhanc
inflamm
mice
enhanc
diseas
result
overexuber
cell
caus
extens
pulmonari
necrosi
acut
capillari
leaklik
syndrom
similar
ard
cell
recruit
abund
cellular
infiltr
natur
depend
cytokin
chemokin
pattern
memori
cell
formalin
vaccin
link
induct
cell
make
induc
strong
pulmonari
eosinophil
respons
possibl
immunotherapeut
enhanc
diseas
includ
cell
deplet
agent
particularli
specif
diseaseenhanc
subset
cytokin
blocker
eg
antitnf
chemokin
blocker
particularli
rant
prior
exposur
balbc
mice
attach
g
fusion
f
protein
rsv
increas
ill
sever
intranas
rsv
challeng
due
lung
eosinophilia
exuber
pulmonari
infiltr
respect
other
use
model
test
potenti
vaccin
immunomodul
exampl
test
detoxifi
mucos
adjuv
deriv
labil
toxin
escherichia
coli
mix
nine
amino
acid
second
matrix
protein
peptid
given
intranas
capabl
induc
protect
cytotox
cell
ctl
reduc
lung
viru
unfortun
ctl
amelior
diseas
fact
made
wors
corollari
observ
model
sign
ill
reduc
antiinfg
antibodi
therapi
simmon
et
al
give
second
exampl
test
antitnf
treatment
mice
shock
lung
induc
ctl
cell
eosinophil
diseas
induc
cell
either
case
benefici
contrast
surfac
ligand
express
cell
reduc
lung
inflamm
sever
ill
mice
immunopatholog
recent
studi
establish
chemokin
rant
appear
import
rant
mrna
protein
level
elev
rsv
infect
particularli
eosinophil
augment
respons
preliminari
block
studi
use
metrant
show
reduc
infiltr
cell
increas
viral
replic
block
studi
underway
addit
area
interest
role
eotaxin
rsv
infect
sinc
chemokin
appear
play
major
role
polar
respons
domin
diseas
unfortun
experiment
model
fail
find
differ
eotaxin
express
particular
form
rsv
diseas
rais
possibl
eosinophil
chemoattract
involv
data
seem
immun
respons
rsv
man
like
balanc
viru
elimin
immun
patholog
current
understand
pathogenesi
bronchiol
support
concept
combin
therapi
antivir
control
viral
replic
immunomodul
control
exuber
immun
respons
would
ration
treatment
approach
complex
diseas
although
aom
gener
consid
bacteri
infect
onethird
aom
case
remain
without
proven
bacteri
etiolog
heikkinen
vast
clinic
experi
connect
aom
viral
upper
respiratori
tract
infect
uri
prompt
investig
search
role
virus
etiolog
aom
convinc
evid
establish
crucial
role
respiratori
virus
etiopathogenesi
aom
role
virus
otiti
media
limit
presenc
mee
middl
ear
effus
aom
fact
virus
could
crucial
role
develop
aom
even
never
enter
middl
ear
caviti
clinic
experi
extens
studi
demonstr
tight
associ
viral
upper
respiratori
infect
aom
henderson
et
al
ruuskanen
et
al
arola
et
al
studi
tempor
develop
aom
young
children
shown
peak
incid
aom
day
onset
symptom
uri
koivunen
et
al
therefor
vast
major
case
children
aom
clearli
regard
complic
uri
direct
evid
role
respiratori
virus
pathogenesi
aom
obtain
detach
mee
children
aom
sinc
investig
attempt
isol
virus
mee
although
data
studi
perform
mainli
influenza
rsv
outbreak
demonstr
isol
virus
mee
yoshi
berglund
et
al
berglund
et
al
overal
detect
rate
virus
remain
lower
sinc
improv
viral
cultur
techniqu
develop
viral
antigen
detect
method
allow
demonstr
virus
viral
antigen
approxim
children
aom
chonmaitre
heikkinen
twothird
case
viru
found
mee
bacteria
also
isol
indic
mix
infect
use
viral
cultur
antigen
detect
method
viru
pathogen
mee
detect
aom
case
develop
pcr
techniqu
substanti
increas
rate
viral
detect
mee
recent
pcrbase
studi
viral
materi
detect
mee
children
aom
okamoto
et
al
et
al
chonmaitre
henrickson
obvious
high
rate
viral
detect
rais
question
whether
viral
nucleic
acid
detect
pcr
repres
virus
real
pathogenet
role
middl
ear
whether
repres
viral
materi
migrat
passiv
nasopharynx
middl
ear
along
nasal
secret
recent
data
indic
differ
variou
respiratori
virus
abil
invad
middl
ear
studi
children
aom
heikkinen
et
al
rel
rate
middleear
invas
rsv
significantli
higher
rate
virus
search
also
parainfluenza
virus
influenza
virus
found
invad
middl
ear
significantli
often
enterovirus
adenovirus
recent
pcrbase
studi
et
al
suggest
rel
preval
rhinoviru
rna
mee
aom
may
similar
rsv
result
suggest
virus
may
enter
middl
ear
passiv
along
nasal
secret
wherea
virus
may
activ
invad
middl
ear
significantli
contribut
inflammatori
process
middl
ear
caviti
presenc
virus
mee
import
regard
etiolog
pathogenesi
aom
virus
may
also
profound
impact
outcom
diseas
studi
children
aom
chonmaitre
et
al
mee
obtain
day
initi
antibiot
treatment
latter
visit
even
though
etiolog
bacteria
suscept
antibiot
use
bacteriolog
failur
observ
children
bacteria
viru
initi
mee
compar
children
bacteria
mee
anoth
studi
children
aom
unrespons
h
antibiot
treatment
arola
et
al
virus
recov
mee
children
compar
children
comparison
group
newli
diagnos
untreat
aom
detail
mechan
virus
may
enhanc
prolong
inflamm
middl
ear
remain
determin
studi
shown
higher
concentr
inflammatori
mediat
mee
contain
bacteria
viru
contain
bacteria
alon
chonmaitre
et
al
chonmaitre
et
al
despit
wellestablish
correl
viral
infect
aom
rate
detect
respiratori
virus
nasopharyng
specimen
children
aom
convent
rang
obviou
howev
limit
viral
cultur
antigen
detect
method
result
underdetect
virus
nasopharyng
specimen
recent
studi
util
pcr
respiratori
virus
found
nasopharyng
specimen
children
aom
heikkinen
et
al
respect
prevent
aom
two
distinct
stage
pathogenesi
diseas
potenti
intervent
could
institut
first
whole
preced
viral
infect
could
prevent
viral
vaccin
would
also
prevent
develop
aom
complic
second
first
day
onset
respiratori
symptom
antivir
drug
could
use
provid
suffici
attenu
viral
infect
develop
aom
could
prevent
clinic
studi
demonstr
approach
effect
sever
influenza
vaccin
trial
shown
prevent
underli
viral
infect
effect
way
prevent
develop
aom
heikkinen
et
al
clement
et
al
belsh
et
al
obviou
vaccin
major
virus
would
also
effect
recent
studi
children
influenza
indic
initi
oseltamivir
treatment
first
h
onset
clinic
symptom
result
reduct
develop
aom
whitley
et
al
summari
viral
infect
play
key
role
otiti
media
initi
whole
cascad
event
final
lead
develop
aom
least
virus
seem
activ
invad
middl
ear
caviti
viralbacteri
interact
may
result
enhanc
inflamm
delay
resolut
diseas
prevent
preced
viral
infect
vaccin
attenu
viral
diseas
antivir
agent
would
effect
prevent
aom
cytotox
lymphocyt
respons
respiratori
infect
guu
rimmelzwaan
erasmu
rotterdam
netherland
cytotox
lymphocyt
ctl
contribut
control
viral
infect
recogn
peptid
viral
protein
present
mhc
class
molecul
infect
cell
recognit
specif
ctl
may
lead
elimin
infect
cell
virus
develop
strategi
evad
recognit
ctl
one
strategi
involv
antigen
variat
ctl
epitop
describ
virus
chronic
infect
host
like
ebv
hiv
hbv
hcv
influenza
virus
caus
acut
respiratori
infect
signific
portion
human
popul
annual
also
escap
ctl
immun
mutat
ctl
epitop
three
variabl
ctl
epitop
influenza
viru
np
recent
describ
first
two
exampl
involv
mutat
posit
np
anchor
residu
restrict
epitop
np
srywairtr
restrict
epitop
np
elrsrywai
previou
studi
shown
mutat
arisen
influenza
season
mutant
variant
complet
replac
viru
strain
contain
wild
type
epitop
furthermor
shown
use
cell
clone
specif
epitop
cell
recognit
complet
abrog
mutat
first
evid
influenza
virus
escap
surveil
specif
ctl
voeten
et
al
third
exampl
variat
influenza
viru
ctl
epitop
associ
escap
ctl
found
newli
identifi
restrict
ctl
epitop
np
boon
et
al
press
defin
minim
epitop
np
use
cell
clone
epitop
predict
program
http
wwwumdsacuktissu
synthet
peptid
found
immunodomin
epitop
exhibit
extens
amino
acid
sequenc
variat
variant
emerg
chronolog
order
variant
studi
similar
bind
affin
molecul
suggest
repres
ctl
epitop
use
cell
clone
polyclon
cell
prepar
direct
previou
current
variant
epitop
recognit
epitop
studi
ctl
specif
older
variant
fail
recogn
recent
strain
influenza
viru
indic
escap
ctl
immun
thu
addit
mutat
surfac
glycoprotein
like
ha
allow
escap
antibodi
mediat
immun
newli
describ
mutat
viral
np
suggest
influenza
virus
also
escap
ctl
mediat
immun
hla
associ
influenza
colin
gelder
wale
cardiff
uk
pilot
studi
look
hla
class
ii
associ
influenza
vaccin
nonrespons
cohort
risk
individu
recruit
singl
famili
practic
england
gelder
et
al
donor
molecularli
hla
class
ii
type
hemagglutin
inhibit
hai
titer
measur
day
subunit
vaccin
nonrespons
defin
failur
mount
hai
respons
compon
trival
influenza
vaccin
associ
failur
mount
hai
respons
influenza
vaccin
locu
found
nonrespond
versu
respond
p
mechan
underli
phenomenon
unclear
though
locu
associ
poor
respons
hepat
b
vaccin
anoth
highli
purifi
subunit
vaccin
propos
donor
may
defect
cell
help
antibodi
product
first
report
polymorph
hla
class
ii
molecul
modul
antibodi
respons
influenza
vaccin
work
need
confirm
popul
elderli
person
repres
highrisk
group
sever
influenza
diseas
pneumonia
death
center
diseas
control
estim
approxim
annual
influenza
epidemicassoci
death
occur
among
person
year
age
acip
recent
studi
indic
rsv
also
major
caus
morbid
mortal
among
elderli
person
zambon
et
al
b
falsey
falsey
walsh
falsey
et
al
drinka
et
al
b
fleme
cross
exacerb
copd
major
caus
morbid
mortal
hospit
glezen
et
al
greenberg
et
al
influenza
rsv
infect
identifi
major
risk
factor
copd
exacerb
walsh
et
al
greenberg
et
al
glezen
et
al
falsey
walsh
mhc
class
irestrict
cytotox
lymphocyt
ctl
activ
thought
play
major
role
recoveri
influenza
rsv
infect
diseas
mcmichael
et
al
mcmichael
recent
design
studi
investig
whether
ctl
activ
influenza
influenza
b
virus
rsv
diminish
elderli
compar
young
adult
assess
impact
copd
ctl
respons
virus
identifi
surrog
ctl
respons
two
high
risk
group
peripher
blood
lymphocyt
pbl
obtain
elderli
copd
subject
control
cohort
match
sex
age
paramet
four
respiratori
viru
epidem
period
preseason
septemberoctob
inseason
novemberjanuari
postseason
marchmay
pbl
sampl
cryopreserv
store
liquid
n
virolog
serolog
test
identifi
total
subject
mean
age
infect
influenza
influenza
b
rsv
nine
copd
patient
control
subject
cell
thaw
stimul
vitro
rsv
influenza
influenza
b
panama
viru
level
ctl
lysi
autolog
target
cell
infect
rsv
influenza
viru
determin
chromium
releas
assay
level
ifng
ctl
cultur
supernat
measur
use
elisa
cryopreserv
cell
healthi
adult
mean
age
year
includ
control
assay
run
differ
occas
elderli
studi
subject
exhibit
significantli
lower
ctl
respons
influenza
influenza
b
rsv
young
adult
control
ctl
respons
influenza
virus
somewhat
higher
among
copd
noncopd
individu
infect
virus
also
slightli
lower
rsvspecif
ctl
respons
display
subject
copd
normal
ifng
surrog
marker
ctl
activ
ctl
antagonist
produc
similar
level
copd
normal
subject
contrast
elderli
person
produc
significantli
lower
ifng
somewhat
higher
level
compar
young
person
result
demonstr
among
elderli
copd
patient
ctl
respons
influenza
virus
rsv
impact
significantli
copd
age
diminish
respons
reduct
ifng
product
among
elderli
person
suggest
type
immun
defici
may
contribut
ctl
deficit
among
elderli
person
role
ctl
defici
increas
morbid
mortal
among
elderli
person
infect
respiratori
virus
requir
evalu
schizophrenia
autism
neurodevelopment
disord
wtih
genet
etiolog
demonstr
monozygot
twin
concordan
rate
respect
mani
hypothes
environment
exposur
predispos
condit
sinc
increas
risk
develop
schizophrenia
autism
offspr
mother
expos
viral
infect
pregnanc
studi
conduct
assess
hypothesi
intranas
infect
day
pregnant
mice
would
caus
structur
abnorm
expos
progeni
neonat
brain
day
analyz
reelin
neuron
nitric
oxid
synthas
nno
grap
immunohistochemistri
western
blot
brain
also
microscop
review
morphometr
analysi
cell
count
reelin
extracellular
protein
describ
defici
patient
schizophrenia
bipolar
affect
disord
depress
lissencephali
autism
found
lower
level
neonat
mice
infect
mother
day
compar
offspr
unexpos
mother
fatemi
fatemi
et
al
fatemi
et
al
c
presynapt
membran
protein
decreas
hippocampu
schizophren
patient
mice
found
higher
day
offspr
born
infect
compar
uninfect
mother
fatemi
et
al
nno
express
abnorm
schizophren
brain
neonat
mice
increas
activ
rostral
area
brain
day
decreas
activ
day
expos
vs
unexpos
mice
fatemi
et
al
gfap
filament
protein
astrocyt
marker
cellular
injuri
found
elev
day
offspr
infect
mice
morpholog
thin
hippocampu
neocortex
day
expos
neonat
pyramid
cell
densiti
increas
nonpyramid
cell
densiti
decreas
day
although
densiti
elev
week
expos
brain
persist
pyramid
cell
atrophi
birth
adulthood
evid
macrocephali
decreas
ventricl
size
adult
expos
mice
final
evid
viral
protein
within
brain
neonat
mice
fatemi
et
al
press
whether
find
specif
influenza
infect
pregnant
mother
unclear
anoth
model
develop
test
hypothesi
offspr
influenza
infect
mother
display
schizophren
behavior
primari
approach
neuropatholog
behavior
sever
behavior
assay
anim
human
directli
compar
lipska
weinberg
includ
anxieti
novel
situat
acoust
startl
respons
repeatedli
found
abnorm
schizophren
geyer
et
al
recent
autist
individu
thought
reflect
difficulti
sensimotor
gate
pregnant
balbc
mice
infect
day
pregnanc
subleth
dose
mouseadapt
human
influenza
viru
behavior
studi
carri
adult
offspr
open
field
test
mice
individu
place
near
center
box
movement
follow
videotap
min
period
novel
object
test
carri
immedi
open
field
test
object
round
silver
cup
social
interact
pair
mice
experiment
control
group
also
examin
place
two
mice
sex
hous
separ
center
box
approxim
cm
apart
monitor
contact
test
offspr
infect
mother
display
behavior
consist
human
schizophrenia
andor
autism
expos
mice
less
like
explor
environ
spent
less
time
center
squar
open
field
enter
center
squar
nearli
less
often
explor
environ
rear
hind
leg
less
often
control
mice
mice
born
infect
mother
also
almost
greater
latenc
first
contact
novel
object
initi
almost
fewer
contact
object
mice
born
sham
infect
mother
social
interact
test
infect
mice
contact
less
frequent
mice
born
sham
infect
mother
acoust
startl
respons
assess
autom
startl
chamber
koch
prepuls
small
caus
startl
preced
startl
stimulu
respons
diminish
phenomenon
term
prepuls
inhibit
ppi
ppi
control
offspr
caus
inhibit
startl
respons
respons
expos
mice
fell
two
group
similar
respons
control
remain
display
strike
deficit
ppi
consist
ppi
find
schizophren
autist
subject
mice
born
infect
mother
also
compar
control
respons
antipsychot
psychomimet
drug
use
ppi
assay
previou
experi
show
acut
administr
dopamin
receptor
block
antipsychot
drug
clozapin
chlorpromazin
increas
ppi
rodent
respons
dramat
accentu
mice
born
infect
mother
suggest
abnorm
dopamin
system
convers
experi
ketamin
glutam
receptor
block
psychomimet
drug
exacerb
psychot
symptom
schizophren
patient
given
mice
well
expect
ppi
control
mice
diminish
ketamin
mice
born
infect
mother
howev
ketamin
enhanc
ppi
suggest
abnorm
glutam
transmitt
pathway
sinc
one
theori
schizophrenia
posit
imbal
dopamineglutamin
system
mice
born
infect
mother
could
well
fit
scenario
quantit
analysi
transmitt
system
requir
test
hypothesi
rais
behavior
result
influenza
model
provid
inform
matern
infect
may
alter
fetal
brain
develop
patterson
press
may
also
prove
use
assess
potenti
intervent
prevent
alter
rsv
adult
ed
walsh
rochest
gener
hospit
rochest
ny
current
time
sever
candid
vaccin
develop
use
adult
includ
purifi
rsv
subunit
protein
subunit
peptid
fragment
chimer
protein
incorpor
neutral
epitop
domin
f
fusion
g
attach
glycoprotein
rsv
addit
limit
work
publish
use
intranas
administ
liveattenu
rsv
vaccin
togeth
subunit
parenter
administ
vaccin
vaccin
phase
ii
clinic
studi
import
select
safe
immunogen
vaccin
use
adult
determin
adult
popul
risk
seriou
rsv
infect
thu
benefit
vaccin
respiratori
tract
infect
variou
adult
popul
winter
recent
prospect
evalu
group
number
per
year
includ
nurs
home
popul
adult
year
age
live
commun
adult
underli
high
risk
condit
copd
andor
chf
live
commun
addit
elderli
person
underli
cardiac
pulmonari
condit
hospit
cardiopulmonari
symptom
evalu
rsv
influenza
viru
infect
identifi
cultur
rtpcr
serolog
rsv
infect
rate
prospect
cohort
annual
similar
incid
rsv
infect
note
among
hospit
group
presenc
copd
chf
signific
risk
factor
hospit
rsv
rsvinfect
hospit
group
one
underli
condit
similar
rate
among
influenzainfect
person
highrisk
elderli
prolong
period
houseand
bedbound
addit
restrict
activ
daili
live
healthi
elderli
person
much
less
like
requir
hospit
rsv
influenza
infect
although
util
health
care
servic
ill
sever
signific
even
among
group
understand
sourc
diseas
import
prevent
rsv
infect
children
sourc
infect
adult
pediatr
immun
might
reduc
attack
rate
elderli
howev
found
among
commun
dwell
adult
document
respiratori
viru
rsv
influenza
b
expos
children
patient
hospit
respect
expos
children
recent
result
suggest
somewhat
higher
risk
influenza
rsv
infect
rel
exposur
children
immun
respons
infect
also
markedli
differ
younger
patient
elderli
cellular
immun
rsv
measur
ifng
elispot
lower
elderli
compar
young
patient
rise
antibodi
titer
result
infect
seen
f
antigen
elderli
young
ga
antigen
respect
gb
antigen
respect
neutral
antibodi
respons
rsv
also
lower
among
young
adult
studi
indic
annual
incid
rsv
infect
approxim
impact
diseas
although
greatest
highrisk
elderli
immunocompromis
inform
current
need
understand
impact
rsv
commun
dwell
adult
better
delin
compon
immun
respons
rsv
protect
pathogen
data
also
make
clear
rsv
vaccin
primarili
target
high
risk
popul
particularli
patient
underli
cardiopulmonari
diseas
rsv
common
caus
respiratori
ill
adult
children
develop
safe
effect
vaccin
great
challeng
aventi
pasteur
develop
rsv
subunit
vaccin
two
adjuv
formul
conduct
two
phase
clinic
studi
intramuscularli
administ
vaccin
compos
copurifi
rsv
protein
f
g
formul
either
aluminum
phosphat
adjuv
rsvalum
poli
di
carboxylatophenoxi
phosphazen
adjuv
rsvpcpp
first
doubleblind
phase
studi
random
forti
healthi
adult
rsvalum
vaccin
n
alumplacebo
vaccin
gener
well
toler
day
local
pain
vs
tender
vs
report
group
particip
local
event
typic
mild
declin
frequenc
week
observ
differ
pain
tender
vaccin
control
group
statist
differ
h
system
advers
event
uncommon
frequent
alumplacebo
arm
month
postvaccin
vaccin
induc
greater
rise
neutral
antibodi
titer
rsv
rsv
b
rsv
b
vacine
respect
greater
rise
antif
antig
antibodi
treat
arm
seen
vacine
respect
second
phase
studi
healthi
young
adult
random
receiv
either
rsvalum
vaccin
rsvpcpp
vaccin
n
local
system
advers
event
similar
two
group
pain
tender
inject
site
common
advers
event
month
postvaccin
rsvalum
result
greater
rise
neutral
antibodi
rsv
rsv
b
rsv
b
particip
rsvpcpp
result
compar
respons
particip
respect
greater
rise
antif
antibodi
seen
rsvalum
rsvpcpp
vaccin
individu
antig
respons
rsvalum
rsvpcpp
vaccin
individu
two
phase
studi
document
formul
safe
immunogen
elicit
greater
equal
rise
neutral
antibodi
rsv
rsv
b
greater
particip
rsv
abas
vaccin
abl
elicit
high
level
neutral
antibodi
rsv
b
protect
rsv
rsv
b
subtyp
would
expect
two
formul
compar
safeti
immunogen
profil
studi
support
clinic
develop
rsv
subunit
vaccin
promis
vaccin
candid
seroposit
popul
includ
elderli
older
children
highrisk
patient
updat
candid
parainfluenza
theodor
tsai
wyeth
pharmaceut
st
pa
parainfluenza
viru
second
rsv
lead
caus
lower
respiratori
tract
ill
infant
glezen
et
al
glezen
et
al
effect
combin
vaccin
could
reduc
significantli
burden
acut
respiratori
ill
among
infant
young
children
phase
clinic
trial
recent
complet
evalu
infect
toler
immunogen
liveattenu
rsv
candid
vaccin
strain
administ
simultan
singl
intranas
dose
strain
deriv
belsh
hissom
serial
passag
human
isol
reduc
temperatur
yield
coldadapt
ca
temperatur
sensit
ts
viru
reduc
replic
capac
lower
respiratori
tract
nonhuman
primat
belsh
hisson
hall
et
al
multipl
mutat
n
c
f
hn
l
protein
n
region
contribut
phenotyp
chang
wild
type
parent
skiadoupolo
et
al
sever
clinic
trial
infant
young
month
strain
well
toler
immunogen
two
dose
regimen
first
dose
provid
protect
challeng
second
dose
reflect
reduc
nasal
viral
shed
shed
first
dose
vs
shed
second
dose
karron
et
al
rsv
strain
deriv
murphi
nih
colleagu
exhibit
similar
phenotyp
ts
attenu
characterist
also
shown
well
toler
immunogen
infant
young
month
month
old
infant
strain
immunogen
also
induc
protect
challeng
second
dose
howev
vaccin
viru
infect
produc
brief
syndrom
mild
nasal
congest
interf
feed
sleep
degre
strain
consid
reactogen
age
group
young
infant
nevertheless
success
experi
strain
older
infant
suggest
rsv
could
combin
clinic
trial
older
infant
proof
principl
combin
intranas
vaccin
multicent
placebocontrol
doubleblind
studi
doubli
seroneg
month
old
healthi
infant
random
receiv
one
two
monoval
vaccin
combin
vaccin
contain
pfu
viru
placebo
singl
ml
intranas
administr
viral
shed
pattern
follow
infect
titrat
serial
nasal
wash
clinic
symptom
follow
diari
card
clinic
examin
viral
shed
rsv
administr
monoval
combin
format
similar
pattern
observ
previou
trial
mean
durat
day
mean
peak
titer
approxim
pfuml
day
shed
administr
alon
also
conform
previou
experi
shed
day
peak
pfu
ml
day
combin
group
howev
proport
vaccine
shed
mean
peak
titer
shed
day
viral
shed
reduc
compar
monoval
group
although
last
significantli
differ
preliminari
analysi
serum
immun
respons
vaccin
show
similar
trend
equal
proport
monoval
combin
subject
respond
antibodi
rise
rsv
smaller
proport
combin
vaccin
recipi
antibodi
rise
wild
type
rsv
virus
circul
commun
infect
subject
demonstr
antibodi
rise
vaccin
placebo
recipi
viral
isol
even
though
trial
confin
week
surveil
detect
epidem
rsv
transmiss
respiratori
symptom
fever
common
similar
frequenc
group
lri
seriou
advers
event
observ
contrari
previou
experi
strain
one
third
recipi
monoval
vaccin
develop
otiti
media
howev
contribut
frequent
nasal
wash
trial
first
week
promot
advers
event
rule
clinic
studi
evalu
safeti
underway
includ
subject
studi
measur
occurr
otiti
media
safeti
event
vaccin
safeti
among
wheezepron
children
vaccin
strain
transmiss
stabil
summari
simultan
administr
rsv
candid
strain
success
infect
major
recipi
larger
trial
need
confirm
safeti
explor
preliminari
observ
suggest
modest
degre
interfer
replic
inclus
final
rsv
vaccin
strain
candid
combin
two
dose
scheme
assess
resist
second
dose
measur
protect
identifi
correl
would
use
econom
influenza
kristin
nichol
minneapoli
va
medic
center
minneapoli
mn
influenza
signific
medic
problem
within
us
year
million
individu
infect
influenza
result
million
lost
work
day
million
lost
school
day
infect
also
caus
excess
hospit
excess
death
year
clear
measur
prevent
infect
use
effect
reduc
influenza
associ
morbitidi
mortal
observ
studi
span
mani
season
differ
countri
consist
shown
influenza
vaccin
result
reduct
pneumonia
influenza
p
hospit
reduct
mortal
among
elderli
nichol
analysi
elderli
chronic
lung
diseas
season
abl
show
season
variat
hospit
seen
among
patient
receiv
annual
influenza
vaccin
anoth
studi
annual
influenza
vaccin
effect
reduc
admiss
rate
p
acut
chronic
respiratori
condit
congest
heart
failur
admiss
addit
reduc
allcaus
mortal
irrespect
risk
statu
elderli
patient
vaccin
result
per
person
cost
save
nichol
et
al
anoth
studi
elderli
larg
hmo
follow
influenza
season
better
assess
benefit
high
vs
low
risk
elderli
event
rate
hospit
death
high
risk
elderli
person
time
higher
among
low
risk
elderli
person
number
elderli
need
vaccin
prevent
singl
hospit
death
studi
high
risk
low
risk
elderli
person
addit
benefit
influenza
pneumococc
vaccin
elderli
well
nichol
healthi
younger
adult
benefit
influenza
vaccin
although
differ
way
elderli
vaccin
result
rel
absolut
risk
reduct
clinic
ill
reduct
serolog
confirm
influenza
infect
reduct
clinic
serolog
infect
greater
good
match
circul
strain
influenza
poor
match
demich
et
al
influenza
vaccin
also
effect
reduc
physician
visit
influenzalik
ill
reduc
antibiot
use
reduc
sick
leav
ahm
et
al
despit
benefit
econom
implic
influenza
vaccin
popul
unclear
individu
studi
find
net
save
other
find
net
cost
nichol
et
al
bridg
et
al
reason
broad
differ
includ
wide
variat
observ
work
loss
reduct
seen
vaccin
studi
reli
econom
model
provid
addit
insight
econom
implic
influenza
vaccin
among
healthi
adult
costutil
analysi
demonstr
vaccin
could
highli
cost
effect
cost
per
year
healthi
life
gain
yhl
age
per
yhl
age
influenza
vaccin
express
dollar
riddiough
et
al
recent
costbenefit
analysi
suggest
vaccin
may
cost
save
analysi
took
societ
perspect
use
nation
repres
estim
accommod
yeartoyear
variabl
influenza
vaccin
effect
incorpor
plausibl
rang
clinic
cost
variabl
model
use
mont
carlo
simul
includ
sensit
analys
incorpor
direct
indirect
cost
vaccin
administr
side
effect
well
avert
cost
doctor
visit
hospit
work
loss
avoid
reduc
effectivenss
avoid
preserv
futur
earn
estim
mean
cost
incur
per
person
vaccin
mean
cost
prevent
result
net
save
percentil
nichol
summari
vaccin
elderli
provid
substanti
health
benefit
cost
save
highest
benefit
among
highrisk
elderli
vaccin
healthi
younger
adult
reduc
ill
provid
visit
work
loss
also
like
provid
econom
benefit
result
influenza
vaccin
may
justifi
adult
unless
priorit
higher
risk
group
mandat
delay
short
suppli
vaccin
reason
current
liveattenu
coldadapt
influenza
vaccin
trace
rout
master
strain
develop
univers
michigan
influenza
influenza
b
annual
updat
liveattenu
influenza
vaccin
laiv
achiev
creat
master
seed
virus
coldadapt
master
strain
undergo
reassort
current
wildtyp
strain
reassort
vaccin
virus
attenu
coldadapt
temperaturesensit
contain
appropri
hemaglutinnin
na
gene
season
potenti
advantag
laiv
vaccin
includ
intranas
rout
administr
well
induct
broad
immun
respons
mucos
well
system
year
mani
studi
demonstr
safeti
efficaci
commerci
laiv
aviron
current
undergo
fda
review
approv
children
adult
flumist
aviron
laiv
administ
children
clinic
trial
demonstr
safeti
efficaci
vaccin
pediatr
efficaci
trial
belsh
et
al
children
age
month
enrol
children
receiv
one
two
dose
vaccin
first
year
trial
random
vaccin
placebo
second
year
trial
children
revaccin
overal
efficaci
vaccin
year
influenza
influenza
b
ill
year
trial
vaccin
efficaci
appear
similar
children
receiv
one
dose
vaccin
vs
overal
mark
differ
cumul
percent
children
infect
influenza
vaccin
children
rel
unvaccin
children
year
reduct
febril
ill
reduct
influenza
cultur
posit
reduct
patient
otiti
media
requir
antibiot
reduct
respect
also
fewer
influenzaassoci
lower
respiratori
tract
complic
children
receiv
vaccin
reduct
trial
show
laiv
safe
gener
well
toler
howev
runni
nose
nasal
congest
vs
fever
vs
common
vaccin
recipi
dose
vaccin
year
signific
differ
seen
dose
year
revaccin
year
costbenefit
analysi
conduct
laiv
vaccin
children
result
break
even
vaccin
cost
groupbas
vaccin
program
individualbas
vaccin
program
societ
perspect
break
even
cost
either
type
program
third
parti
payer
perspect
luce
et
al
flumist
laiv
also
test
adult
underli
immunodefici
n
hiv
infect
underli
lung
diseas
n
largest
studi
work
adult
adult
random
receiv
laiv
placebo
studi
outcom
use
clinic
definit
ill
vaccin
abl
reduc
proport
person
febril
ill
sever
febril
ill
febril
upper
respiratori
ill
also
reduct
ill
day
reduct
miss
day
work
reduct
provid
visit
reduct
day
antibiot
prescrib
p
b
although
vaccin
placebo
recipi
runni
nose
sore
throat
immun
vaccin
gener
well
toler
advers
symptom
mild
short
durat
nichol
et
al
smaller
experiment
volunt
challeng
studi
protect
influenza
b
virus
induc
laiv
trival
inactiv
vaccin
found
mark
reduct
laboratorydocu
influenza
ill
recipi
laiv
compar
placebo
vaccin
efficaci
rate
significantli
differ
vaccin
ci
laiv
ci
inactiv
vaccin
treanor
et
al
final
yet
unpublish
data
recent
costbenefit
analysi
young
healthi
adult
found
mean
break
even
vaccin
cost
ci
laiv
use
among
healthi
work
adult
summari
flumist
laiv
highli
effect
prevent
influenza
healthi
children
young
adult
gener
safe
welltoler
easi
administ
current
studi
done
look
coadministr
mmrii
varivax
vaccin
month
studi
also
plan
look
extend
pediatr
commun
effectiv
trial
fourth
year
assess
safeti
vaccin
children
wheez
ill
asthma
look
coadministr
prevnar
hib
dtap
ipv
vaccin
month
berna
reinhard
berna
bern
switzerland
nasal
administ
influenza
vaccin
focus
us
liveattenu
candid
vaccin
contrast
nonrepl
virosom
intranas
vaccin
test
approv
use
switzerland
nasalflu
berna
trival
influenza
viru
vaccin
consist
influenza
virosom
formul
inactiv
influenza
surfac
glycoprotein
lecithin
heatlabil
toxin
escherigen
e
coli
bacteria
strain
mucos
adjuv
hlt
particl
nm
diamet
deliv
nasal
spray
devic
phosphat
buffer
salin
solut
preliminari
test
multipl
anim
model
show
vaccin
safe
immunogen
mice
good
respons
vaccin
increas
level
iga
igg
lung
bal
blood
mice
requir
two
dose
achiev
adequ
iga
respons
ferret
vaccin
abl
inhibit
fever
inflammatori
cell
influx
weight
loss
follow
experiment
infect
ferret
also
demonstr
mark
reduct
viral
titer
b
log
vs
log
compar
unvaccin
anim
extens
toxic
test
conduct
sever
primat
nonprim
anim
found
seriou
toxic
even
dose
high
time
usual
human
dose
clinic
prepar
use
mcg
ha
antigen
per
strain
mcg
lecithin
mcg
escherigen
administ
twice
week
period
sinc
markedli
improv
immunogen
two
dose
rel
one
dose
two
dose
vaccin
regimen
abl
induc
rise
igg
antibodi
titer
recipi
b
vaccin
efficaci
trial
adult
efficaci
children
glueck
signific
advers
event
note
studi
result
vaccin
licens
use
switzerland
vaccin
wide
accept
use
first
season
influenza
season
peopl
given
vaccin
report
case
bell
palsi
recipi
vaccin
occur
pharmaceut
compani
make
vaccin
suspend
sale
investig
relationship
detail
berna
sent
survey
swiss
physician
found
case
bell
palsi
countri
whole
number
case
appear
higher
usual
rate
preliminari
analysi
fail
show
clear
correl
time
vaccin
develop
bell
palsi
investig
potenti
side
effect
ongo
genet
approach
influenza
peter
pales
mt
sinai
school
medicin
new
york
ny
genet
makeup
virus
better
understood
genet
alter
influenza
virus
becom
avail
potenti
vaccin
candid
recent
protein
identifi
virul
factor
influenza
virus
protein
absent
viru
highli
attenu
protein
respons
interferon
antagonist
activ
grown
cultur
system
knockout
mice
unabl
produc
interferon
defici
influenza
viru
regain
wildtyp
virul
garciasastr
et
al
result
find
sever
influenza
viru
construct
develop
truncat
gene
influenza
viru
experi
conduct
mice
immun
virus
contain
either
wildtyp
alter
gene
mice
challeng
wild
type
viru
week
immun
mice
challeng
immun
mutant
viru
surviv
talon
et
al
protect
seen
mice
immun
low
dose
viru
lack
gene
pfu
vs
current
studi
plan
assess
efficaci
defici
virusbas
vaccin
human
gene
appear
confer
virul
gene
influenza
viru
analyz
compar
viru
use
mous
experi
viru
contain
ns
gene
creat
grown
tissu
cultur
strain
appear
virul
induc
death
infect
balbc
mice
viru
caus
univers
fatal
pfu
inocul
find
suggest
protein
viru
may
possess
speciesspecif
activ
unabl
counteract
interferon
respons
mous
basler
et
al
whether
protein
confer
high
virul
phenotyp
human
remain
determin
anoth
recent
advanc
use
newcastl
diseas
viru
ndv
vaccin
vector
influenza
viru
ha
gene
splice
genom
ndv
recombin
viru
stabl
abl
effect
produc
influenza
antigen
without
caus
diseas
mice
studi
mice
given
pfu
day
challeng
day
done
vaccin
abl
produc
high
level
hi
titer
viru
vaccin
mice
whether
vaccin
given
iv
ip
vaccin
attenu
weight
loss
allow
mice
surviv
challeng
none
unvaccin
mice
surviv
nakaya
et
al
studi
suggest
futur
influenza
vaccin
may
deriv
genet
alter
influenza
virus
virus
includ
ndv
genet
alter
produc
protect
influenza
antigen
host
excit
develop
warrant
studi
boost
immun
prime
popul
iainstephenson
leicest
royal
infirmari
leicest
uk
past
sever
year
heighten
concern
emerg
influenza
strain
caus
next
influenza
pandem
prevent
virul
agent
could
best
accomplish
vaccin
recent
studi
conduct
establish
util
novel
adjuv
vaccin
vaccin
prepar
oilinwat
emuls
solubl
squalen
polysorb
surfac
antigen
soluabl
sorbitan
trioleat
citrat
buffer
steril
water
observ
blind
random
doserang
studi
conduct
healthi
young
adult
nicholson
et
al
patient
receiv
intramuscular
dose
week
apart
either
mg
ha
content
adjuv
plain
vaccin
microneutralis
mn
test
hemagglutin
inhibit
test
singl
radial
hemolysi
srh
test
ahong
virus
studi
demonstr
hi
insensit
detect
antibodi
compar
mn
srh
adjuv
vaccin
well
toler
greater
antibodi
respons
day
unadjuv
vaccin
followup
studi
conduct
determin
durabl
respons
residu
immun
month
assess
effect
singl
addit
vaccin
immun
respons
prime
group
followup
studi
unblind
patient
receiv
dosag
vaccin
receiv
initi
studi
adjuv
vaccin
well
toler
fifteen
month
receiv
first
two
vaccin
detect
immun
hi
mn
method
although
small
detect
residu
antibodi
level
srh
greatest
mg
group
adjuv
vaccin
group
twentyon
day
booster
dose
vaccin
minim
respons
hi
modest
srh
nonadjuv
arm
respons
far
robust
adjuv
arm
maximum
geometr
mean
titer
hi
mm
srh
srh
nearli
mm
degre
respons
irrespect
method
use
higher
booster
dose
month
second
dose
initi
seri
final
number
patient
seroconvert
hi
day
booster
vaccin
plain
vaccin
group
respect
seroconvers
srh
respect
two
studi
abl
demonstr
adjuv
vaccin
result
greater
respons
unadjuv
vaccin
revaccin
month
success
boost
immun
respons
particularli
adjuv
group
data
also
suggest
hi
respons
gener
underestim
antibodi
respons
compar
mn
srh
new
influenza
nasal
administr
use
chitosan
absorpt
enhanc
roy
jen
sheffield
sheffield
uk
current
influenza
vaccin
formul
inactiv
prepar
administ
parenter
contain
either
surfac
ha
na
protein
viru
whole
viru
particl
suboptim
vaccin
induc
immun
best
vaccine
individu
extrem
age
respond
particularli
poorli
respiratori
mucos
immun
respons
contribut
significantli
natur
immun
strategi
improv
current
influenza
vaccin
may
administr
influenza
vaccin
via
mucos
rout
anim
studi
influenza
vaccin
incorpor
varieti
adjuv
deliv
intranas
rout
report
good
local
system
antibodi
respons
protect
subsequ
challeng
infect
new
influenza
vaccin
incorpor
chitosan
deacyl
form
chitin
obtain
shrimp
crab
shell
current
commerciallyavail
subunit
influenza
viru
vaccin
recent
develop
solvay
weesp
netherland
initi
studi
administ
chitosaninfluenza
vaccin
formul
healthi
adult
volunt
age
year
studi
anim
human
indic
mucoadhes
properti
chitosan
enhanc
bioavail
protein
follow
intranas
administr
chitosan
shown
safe
human
nasal
toxic
advers
effect
mucociliari
clearanc
studi
carri
use
commerci
subunit
influenza
vaccin
contain
influenza
b
antigen
mix
two
concentr
level
mgml
chitosan
fullstrength
mg
half
strength
mg
amount
viral
antigen
use
experiment
vaccin
addit
commerci
influenza
vaccin
contain
mg
viral
antigen
without
chitosan
employ
gold
standard
studi
recruit
volunt
receiv
fullstrength
chitosaninfluenza
vaccin
halfstrength
chitosaninfluenza
vaccin
prepar
intranas
spray
separ
occas
day
apart
volunt
given
singl
dose
commerci
vaccin
intramuscular
rout
blood
sampl
collect
prior
vaccin
regular
interv
subsequ
result
show
hi
antibodi
seroconvers
rate
asydney
moieti
vaccin
similar
follow
intranas
deliveri
full
strength
chitosaninfluenza
vaccin
intramuscularlydeliv
unadjuv
commerci
vaccin
howev
case
influenza
b
moieti
vaccin
seroconvers
rate
greater
follow
intramuscular
vaccin
deliveri
nevertheless
respect
influenza
type
viru
ha
antigen
vaccin
intranas
deliveri
dose
chitosaninfluenza
prepar
full
strength
elicit
seroconvers
volunt
therebi
meet
committe
proprietari
medicin
product
influenza
vaccin
cpmp
requir
furthermor
abeij
vaccin
compon
halfstrength
prepar
chitosaninfluenza
vaccin
also
met
requir
requir
cpmp
respect
protect
rate
serum
hi
antibodi
titr
equal
greater
experiment
influenza
vaccin
healthi
adult
vaccin
achiev
vaccine
present
studi
level
achiev
follow
vaccin
dose
respect
asydney
influenza
b
chitosaninfluenza
vaccin
compon
fulland
halfstrength
dosag
level
also
halfstrength
dosag
level
abeij
chitosaninfluenza
vaccin
compon
three
vaccin
compon
intramuscularlyadmimist
standard
commerci
vaccin
induc
protect
rate
cpmp
requir
level
nasallyadminist
chitosaninfluenza
vaccin
use
present
studi
well
toler
volunt
full
strength
prepar
advers
event
report
mild
primarili
rhiniti
short
durat
none
sever
respect
half
strength
chitosaninfluenza
vaccin
prepar
advers
event
report
mild
two
sever
advers
event
group
unconnect
vaccin
program
summari
influenza
vaccin
studi
show
nasal
administr
prepar
safe
welltoler
elicit
serum
hi
antibodi
respons
least
compon
vaccin
reach
level
seroconvers
protect
compli
cpmp
guidelin
experiment
influenza
vaccin
healthi
adult
volunt
overlap
clinic
present
rsv
influenza
signific
among
elderli
person
underli
copd
chf
true
hospit
person
outpati
howev
influenza
infect
person
tend
higher
temperatur
rsv
infect
person
higher
rate
wheez
nasal
congest
influenza
also
often
associ
chest
pain
rhonchi
rale
infiltr
chest
xray
short
durat
ill
rsv
infect
often
associ
sputum
product
dyspnea
longer
durat
ill
diagnosi
rsv
adult
depend
upon
laboratori
test
cultur
rtpcr
serolog
among
adult
evalu
rsv
infect
identifi
rsv
cultur
posit
subject
pcr
serolog
overal
found
sensit
pcr
among
outpati
among
hospit
person
specif
contrast
cultur
sensit
rapid
antigen
detect
sensit
consider
overlap
symptom
associ
variou
respiratori
virus
differ
exist
advantag
taken
differ
develop
clinic
predictor
specif
viral
etiolog
respiratori
infect
predictor
use
number
way
current
princip
one
determin
situat
influenza
antivir
use
treatment
least
two
studi
shown
cough
fever
import
predictor
type
b
influenza
monto
et
al
monto
ohmit
note
degre
temperatur
elev
appear
increas
likelihood
influenza
addit
correl
time
relief
symptom
monto
et
al
howev
data
came
physicianbas
surveil
respiratori
ill
period
high
low
influenza
viru
activ
posit
predict
valu
ppv
cough
fever
carrat
et
al
contrast
demonstr
influenza
transmiss
occur
commun
prerequisit
enrol
studi
antivir
treatment
influenza
thu
influenza
infect
frequenc
higher
entir
winter
season
follow
data
zanamivir
studi
examin
found
ppv
cough
fever
influenza
posit
higher
fever
better
predict
valu
note
also
patient
benefit
antivir
treatment
canadian
studi
similarli
conduct
period
influenza
viru
transmiss
ppv
cough
fever
greater
part
high
ppv
result
high
preval
influenza
infect
boivin
et
al
particular
problem
differenti
influenza
respiratori
virus
children
influenza
season
recent
studi
found
cough
fatigu
headach
myalgia
chill
strongli
relat
influenza
infect
expiratori
wheez
good
predictor
infect
although
fever
predict
influenza
infect
signific
ci
p
manuguerra
et
al
data
respiratori
viral
infect
limit
studi
pleconaril
two
symptom
congest
rhinorrhea
appear
common
rhinovir
cold
unfortun
differ
rhinovir
nonrhinovir
cold
congest
vs
rhinorrhea
vs
small
suggest
rapid
test
influenza
might
use
time
influenza
virus
circul
sporad
howev
even
assum
good
sensit
test
ppv
similarli
fall
period
low
viru
transmiss
indic
mani
true
posit
miss
moreov
laboratori
studi
use
frozen
specimen
shown
sensit
may
much
lower
tabl
interest
data
suggest
markedli
lower
sensit
directogen
b
detect
influenza
virus
compar
directogen
test
sensit
evalu
outbreak
studi
found
problem
specif
among
posit
test
quickvu
flu
oia
differ
nurs
home
sampl
neg
cell
cultur
pcr
fals
posit
test
result
outbreak
incorrectli
identifi
caus
influenza
summari
symptom
cough
fever
consist
predict
influenza
viru
infect
influenza
preval
high
predict
valu
improv
increas
fever
influenza
infect
predict
adult
much
eas
children
age
rapid
test
least
help
influenza
viru
preval
low
care
must
taken
rapid
test
sensit
specif
yet
optim
situat
final
predict
rhinoviru
posit
may
possibl
use
similar
clinic
predict
model
manag
analysi
larg
genet
sequenc
data
set
catherin
macken
lo
alamo
nation
laboratori
lo
alamo
nm
past
decad
technolog
advanc
allow
sequenc
genom
sever
organ
sequenc
tend
larg
difficult
share
recent
influenza
sequenc
databas
isd
http
wwwflulanlgov
establish
lo
alamo
nation
laboratori
theoret
biolog
biophys
group
serv
site
influenza
genom
sequenc
store
analyz
share
influenza
sequenc
databas
curat
databas
nucleotid
amino
acid
sequenc
intend
provid
research
commun
easi
sequenc
deposit
retriev
capabl
togeth
tool
tailor
particular
analysi
ha
na
sequenc
care
taken
remov
redund
sequenc
fill
miss
field
data
project
began
spring
databas
hold
influenza
b
c
sequenc
publish
genbank
well
grow
number
unpublish
sequenc
research
interest
deposit
unpublish
sequenc
directli
isd
via
passwordprotect
web
site
via
email
direct
catherin
macken
cmacken
lanlgov
order
provid
search
blast
servic
pull
redund
entri
new
sequenc
review
receiv
ensur
adequ
qualiti
complet
compar
previou
sequenc
two
genbank
nucleotid
record
correspond
influenza
strain
contain
ident
sequenc
classifi
except
one
duplic
current
take
protein
sequenc
crossreferenc
pid
genbank
nucleotid
sequenc
primari
protein
sequenc
exist
genbank
nucleotid
sequenc
translat
protein
record
take
protein
sequenc
anoth
databas
latter
event
rare
occur
case
strain
duplic
result
tabl
sensit
antigen
detect
test
frozen
specimen
use
cell
cultur
gold
standard
structur
studi
secondari
tertiari
structur
inform
chang
sequenc
classifi
duplic
sequenc
structur
studi
structur
duplic
primari
protein
sequenc
match
final
anoth
sourc
duplic
record
resequenc
gene
origin
partial
sequenc
extens
coverag
gene
later
sequenc
effort
situat
classifi
except
longest
sequenc
duplic
provid
sequenc
ident
region
overlap
data
store
relat
databas
allow
correl
epidemiolog
genet
virolog
inform
user
perform
basic
advanc
search
well
two
special
function
call
region
prosit
search
region
search
advanc
search
addit
featur
allow
user
prune
return
sequenc
region
interest
region
search
base
prealign
sequenc
henc
use
download
align
prosit
search
anoth
advanc
search
applic
protein
sequenc
addit
featur
identifi
prosit
pattern
prosit
search
use
colorcod
glycosyl
site
ctl
epitop
pattern
interest
onto
prealign
protein
sequenc
site
also
includ
analyt
tool
allow
user
select
highlight
residu
dynam
visual
crystal
structur
ha
use
rasmol
anoth
tool
translat
access
number
usersuppli
phylogenet
tree
full
abbrevi
strain
name
tool
develop
stage
data
avail
multipl
format
download
recent
innov
capac
hous
privat
compart
site
compart
use
public
data
site
data
data
visibl
exampl
serv
need
neuraminidas
inhibitor
suscept
network
nisn
privat
compart
creat
use
public
view
databas
member
nisn
view
compart
databas
databas
expens
undertak
requir
number
highli
train
highli
skill
individu
maintain
constantli
improv
upon
input
user
ryan
health
research
center
san
diego
ca
outbreak
respiratori
ill
due
adenovirus
describ
militari
recruit
sinc
increas
risk
part
due
stress
train
environment
factor
sudden
mix
suscept
young
adult
close
contact
set
adenoviru
associ
attack
rate
adenoviru
caus
recruit
hospit
acut
respiratori
ill
militari
personnel
winter
month
attribut
adenoviru
oral
live
attenu
vaccin
adenoviru
serotyp
develop
new
militari
recruit
requir
receiv
vaccin
vaccin
sole
produc
wyeth
lederl
vaccin
discontinu
product
vaccin
remain
suppli
use
limit
fashion
usabl
vaccin
current
remain
address
loss
vaccin
us
depart
defens
award
contract
barr
pharmaceut
begin
make
vaccin
unfortun
vaccin
wide
avail
depart
defens
center
deploy
health
research
http
wwwnhrcnavymil
given
task
assess
current
impact
adenoviru
militari
attempt
provid
inform
help
guid
vaccin
develop
assess
variou
control
method
center
deploy
health
research
surveil
us
militari
basic
train
site
includ
collect
popul
demograph
clinic
present
data
young
adult
febril
respiratori
ill
provid
throat
swab
specimen
test
presenc
virus
cell
cultur
sinc
discontinu
routin
vaccin
adenoviru
trend
toward
case
adenovir
respiratori
infect
averag
recruitsweek
last
year
avail
vaccin
week
addit
epidem
adenovir
outbreak
defin
greater
recruitsweek
militari
basic
train
camp
everi
year
sinc
cessat
stark
contrast
rare
epidem
vaccin
adenovir
ill
case
occur
popul
ryan
et
al
press
includ
fatal
case
case
still
caus
adenoviru
type
follow
frequenc
type
unvaccin
recruit
time
like
posit
adenoviru
cultur
ci
time
like
posit
type
adenoviru
ci
vaccin
personnel
case
adenoviru
infect
present
fever
greater
complic
averag
day
reduc
activ
day
respiratori
diseas
patient
infect
caus
type
adenoviru
typic
present
nasal
congest
sore
throat
cough
gastrointestin
disturb
use
multivari
analysi
center
conclud
lack
vaccin
repres
greatest
risk
adenovir
infect
odd
ratio
greater
model
addit
risk
factor
includ
autumn
recruit
home
state
kansa
new
mexico
smoke
statu
nonsmok
great
risk
type
infect
gender
age
race
past
respiratori
diseas
associ
adenovir
infect
costeffect
analys
found
vaccin
benefici
maintain
militari
readi
battl
hyer
et
al
new
era
healthcar
cost
contain
thoma
szuc
hirslanden
hold
zurich
switzerland
past
sever
decad
healthcar
cost
increas
substanti
result
mani
factor
includ
new
treatment
previous
untreat
condit
new
evid
support
broader
applic
exist
treatment
overal
increas
cost
treatment
greater
develop
area
biolog
expens
increas
intens
treatment
qualiti
improv
measur
increas
demand
better
educ
public
enorm
growth
cost
led
renew
interest
cost
contain
increas
interest
cost
contain
deriv
age
popul
result
antiegalitarian
trend
pay
higher
copay
healthcar
addit
observ
increas
gap
medicin
afford
handinhand
increas
interest
come
wider
use
evidencebas
medicin
technolog
assess
better
assess
costli
intervent
produc
greatest
benefit
cost
contain
current
focus
price
reduct
increas
competit
price
control
demand
reduct
reimburs
limit
manag
care
budget
global
healthcar
budget
countri
certif
need
drug
approv
pharmaceut
overal
benefici
effect
life
expect
total
health
care
cost
also
clear
specif
benefit
use
antivir
especi
na
inhibitor
antivir
directli
reduc
cost
reduc
number
followup
consult
antibiot
use
reduc
incid
complic
result
hospit
direct
cost
estim
averag
billion
europ
billion
us
annual
indirectli
antiinfluenza
treatment
improv
product
contribut
costeffect
indirect
cost
influenza
amount
billion
europ
billion
us
annual
increment
costeffect
zanamivir
per
symptomsfre
gain
day
sever
estim
rang
base
decemb
convers
data
griffin
et
al
mauskopf
et
al
unfortun
costeffect
analys
headtohead
compar
differ
therapeut
option
none
done
refer
qualiti
adjust
life
year
qali
result
uk
nation
institut
clinic
excel
nice
initi
decid
recommend
widespread
use
zanamivir
chang
stanc
recommend
zanamivir
use
atrisk
adult
influenza
circul
commun
patient
present
within
h
onset
ill
potenti
impact
decis
use
atrisk
individu
would
yield
cost
million
revers
posit
brought
two
costeffect
studi
referenc
qali
first
conduct
nice
estim
adult
influenza
circul
qali
atrisk
adult
influenza
circul
base
assess
clinic
effect
estim
drug
cost
addit
physician
visit
cost
hospit
nice
technolog
apprais
addit
evid
studi
atrisk
patient
assum
reduct
mortal
baselin
influenza
infect
individu
ad
first
model
result
estim
outsid
england
nice
chang
take
place
profound
effect
drug
approv
rel
costeffect
mani
countri
throughout
europ
requir
two
step
drug
approv
registr
drug
ministri
health
agreement
price
allow
new
drug
ad
nation
formulari
price
base
mandat
pharmacoeconom
analysi
nearli
everi
countri
agenc
provid
econom
guidelin
celibera
cipe
n
although
pharmacoeconom
analys
like
result
cost
save
overal
difficulti
implement
harmon
move
forward
registr
new
drug
without
similar
harmon
costset
practic
industri
academia
govern
concern
develop
antivir
resist
subsequ
impact
influenza
diseas
follow
widespread
avail
use
neuraminidas
inhibitor
ni
point
licens
drug
known
impact
resist
ni
drug
treatment
infect
evolut
viru
particularli
regard
antigen
result
establish
resist
monitor
group
compon
licens
approv
clinic
avail
ni
drug
neuraminidas
inhibitor
suscept
network
nisn
establish
fulfil
goal
zambon
hayden
nisn
current
fund
roch
pharmaceut
glaxosmithklin
compos
core
vote
membership
compos
collabor
center
alan
hay
alan
hampson
alexand
klimov
masato
toshiro
member
academ
public
health
commun
jenni
mckimmbreschkin
robert
webster
arnold
monto
michel
aymard
catherin
macken
frederick
hayden
maria
zambon
well
observ
sponsor
pharmaceut
compani
world
health
organ
current
nisn
establish
link
two
sponsor
compani
valid
assay
phenotyp
resist
compar
resist
assay
perform
panel
virus
mix
experi
wild
type
known
resist
mutant
also
collect
analys
na
inhibitori
concentr
influenza
isol
collect
worldwid
prior
introduct
ni
drug
select
isol
outlier
phenotyp
screen
sequenc
attempt
correl
phenotyp
genotyp
data
resist
current
avail
ni
zanamivir
oseltamivir
occur
result
mutat
na
gene
result
decreas
bind
affin
ni
mutat
ha
gene
result
decreas
affin
sialic
acid
resist
variant
recov
low
incid
oseltamivir
case
zanamivir
typic
late
cours
ill
patient
prolong
shed
niresist
viru
due
na
mutat
appear
less
effici
infect
new
cell
appear
transmit
human
associ
date
rebound
viral
replic
welliv
et
al
method
assess
phenotyp
resist
develop
includ
na
inhibit
assay
without
genotyp
na
mutant
studi
identifi
distinct
na
mutat
associ
resist
one
ni
mix
experi
compar
fluorometr
chemiluminesc
ni
method
indic
shape
resist
curv
depend
mutant
method
use
similar
valu
obtain
differ
method
date
sampl
collect
introduct
ni
studi
use
sampl
nisn
shown
deriv
fluoromet
analysi
compar
chemiluminesc
method
chemiluminesc
select
primari
method
screen
sampl
resist
allow
highest
throughput
lowest
variabl
use
method
known
resist
variant
outsid
sampl
outlier
rule
accept
limit
virus
analys
resist
genotyp
precis
orient
immedi
surround
residu
conserv
na
site
may
differ
subtyp
drug
bind
may
ident
across
subtyp
preliminari
data
appear
differ
drug
may
produc
differ
resist
pattern
resist
strategi
may
ident
across
subtyp
viru
analys
isol
appear
wide
variat
natur
isol
signific
variat
year
geographi
futur
hope
conduct
sequenc
analysi
na
ha
outlier
virus
analys
isol
follow
introduct
drug
use
delin
relationship
genotyp
phenotyp
resist
conduct
detail
analysi
preand
posttreat
isol
effect
dissemin
data
commun
flunet
approach
influenza
manag
simon
tucker
biota
hold
limit
melbourn
australia
flunet
technolog
establish
discov
new
neuraminidas
inhibitor
long
resid
time
respiratori
tract
high
potenc
ultim
goal
produc
novel
drug
could
dose
daili
treatment
weekli
prophylaxi
cooper
work
biota
hold
limit
glaxosmithklin
lead
design
sever
multimer
zanamivir
molecul
link
hydroxi
group
initi
test
dimer
trimer
tetram
conduct
screen
potenti
drug
develop
screen
vitro
activ
six
influenza
four
influenza
b
virus
reveal
dimer
extrem
potent
median
ec
approach
mgml
cell
cultur
next
number
linker
atom
two
zanamivir
molecul
vari
activ
assess
virus
preliminari
experi
show
greatest
activ
found
linker
atom
substanti
lower
activ
shorter
linker
evid
reduc
activ
longer
linker
exampl
dimer
carbon
alkyl
linker
ec
ngml
ngml
cytopath
effect
assay
rat
lung
retent
studi
done
deliv
mgkg
studi
drug
zanamivir
via
intratrach
instil
level
dimer
within
lung
remain
approxim
ngg
tissu
day
significantli
excess
ec
median
ec
ngml
zanamivir
declin
substanti
level
approach
ec
approxim
ngml
prophylact
studi
conduct
mice
dose
dimer
zanamivir
infect
influenza
day
administr
dose
protect
zanamivir
dose
mice
evid
high
dosag
group
receiv
mgkg
wherea
suffici
dimer
remain
week
reduc
viral
titr
dose
low
mgkg
final
treatment
experi
use
zanamivir
twice
day
dimer
mgkg
dose
singl
administr
dimer
found
yield
equival
reduct
viral
titr
compar
untreat
mice
twice
daili
zanamivir
studi
suggest
increas
aggreg
viru
treat
dimer
rel
monomer
zanamivir
provid
possibl
explan
increas
potenc
crossresist
occur
dimer
monomer
zanamivir
indic
act
na
current
biota
lead
select
studi
determin
agent
would
best
move
forward
develop
treatment
elderli
longterm
care
resid
nanci
risebrough
mount
sinai
hospit
toronto
canada
therapi
neuraminidas
inhibitor
effect
reduc
symptom
durat
sever
healthi
adult
infect
influenza
therapeut
efficaci
resid
longterm
care
facil
yet
fulli
describ
data
collect
part
compassion
use
program
manag
influenza
outbreak
residenti
long
term
care
facil
ltcf
elderli
ontario
canada
influenza
season
resid
staff
facil
receiv
influenza
vaccin
fall
oseltamivir
offer
resid
facil
outbreak
influenza
due
five
outbreak
transmiss
influenza
occur
despit
amantadin
prophylaxi
oseltamivir
offer
resid
treatment
prophylaxi
remain
six
resid
offer
choic
amantadin
oseltamivir
outbreak
recogn
data
collect
daili
everi
day
statu
outbreak
retrospect
chart
review
done
identifi
antibiot
use
influenza
complic
hospit
death
patient
develop
influenza
receiv
amantadin
prophylaxi
offer
oseltamivir
mg
twice
daili
day
ill
resid
taken
amantadin
previous
offer
either
amantadin
mg
day
dose
adjust
creatinin
clearanc
oseltamivir
patient
compar
regard
age
sever
ill
baselin
adl
capac
vaccin
statu
patient
influenzalik
ill
patient
cultur
pcr
document
influenza
receiv
therapi
receiv
amantadin
h
symptom
onset
receiv
oseltamivir
h
onset
symptom
receiv
oseltamivir
within
h
symptom
onset
receiv
oseltamivir
prophylaxi
continu
oseltamivir
therapi
patient
start
oseltamivir
less
h
onset
symptom
oseltamivir
prophylaxi
significantli
complic
hospit
death
rel
receiv
therapi
amantadin
delay
oseltamivir
fewer
antibiot
prescrib
resid
receiv
earli
specif
influenza
therapi
tabl
oseltamivir
well
toler
overal
resid
advers
event
one
confus
dizzi
headach
treatment
influenza
antivir
outbreak
ltcf
associ
reduc
rate
antibiot
use
earli
treatment
oseltamivir
appear
associ
reduc
rate
seriou
complic
compar
treatment
amantadin
canada
amantadin
postexposur
prophylaxi
pep
standard
care
ili
prevent
ltcf
costeffect
oseltamivir
pep
unknown
costeffect
model
develop
examin
cost
outcom
manag
strategi
oseltamivir
pep
compar
amantadin
pep
prophylaxi
canadian
govern
perspect
vaccin
elderli
ltcf
popul
day
prophylaxi
initi
follow
confirm
influenza
outbreak
ltcf
event
model
drug
relat
advers
event
emerg
ili
prophylaxi
use
antibiot
ili
complic
caus
mortal
resist
amantadin
estim
ltcf
would
influenza
outbreak
facil
patient
would
develop
ili
without
prophylaxi
without
prophylaxi
patient
ili
develop
seriou
complic
die
probabl
determin
random
control
trial
observ
studi
base
avail
literatur
ltcf
without
identifi
amantadin
resist
amantadin
pep
reduc
risk
develop
ili
oseltamivir
pep
cost
drug
lab
physician
visit
acut
hospit
day
includ
base
canadian
govern
sourc
publish
literatur
assum
patient
receiv
amantadin
dose
adjust
accord
creatinin
clearanc
cost
cdn
per
patient
laboratori
studi
cost
pharmacist
nurs
time
dose
calcul
includ
result
show
compar
prophylaxi
oseltamivir
save
per
patient
prevent
ili
case
per
patient
compar
amantadin
oseltamivir
save
per
patient
prevent
ili
case
per
patient
cost
amantadin
dose
adjust
signific
cost
amantadin
pep
strategi
compar
prophylaxi
analysi
pep
strategi
save
overal
health
care
cost
despit
addit
drug
acquisit
cost
base
result
prophylaxi
oseltamivir
costeffect
influenza
prevent
strategi
ltcf
environ
winther
virginia
va
influenza
enter
host
deposit
eye
nose
typic
hand
inhal
anatomi
upper
airway
optim
enhanc
influenza
viru
deposit
nasopharynx
proetz
deposit
readili
infect
adenoid
epithelium
winther
et
al
may
also
spread
sinus
eustachian
tube
middl
ear
recent
studi
shown
nose
blow
sneez
cough
capabl
rais
intranas
pressur
high
mmhg
studi
use
iodin
contrast
demonstr
passag
materi
nasopharynx
sinus
nose
blow
gwaltney
et
al
current
littl
inform
exist
involv
sinus
influenza
infect
children
children
common
cold
symptom
less
h
major
evid
sinus
ct
scan
day
day
schwartz
et
al
although
difficult
diagnos
clinic
therefor
like
sinus
involv
influenza
infect
children
may
lead
viral
bacteri
mix
viralbacteri
sinus
attent
recent
place
role
influenza
middl
ear
infect
eustachian
tube
dysfunct
alter
middl
ear
pressur
detect
tympanogram
occur
influenza
infect
patient
prophylact
intranas
zanamivir
adult
infect
experiment
influenza
effect
prevent
abnorm
tympanogram
vs
placebo
treat
patient
walker
et
al
influenza
appear
risk
factor
aom
whether
diagnos
clinic
abnorm
pneumat
otoscopi
compat
clinic
syndrom
fever
earach
irrit
poor
sleep
eat
respiratori
gastrointestin
symptom
rtpcr
detect
viral
rna
mef
influenza
vaccin
children
enrol
daycar
appear
reduc
diagnosi
aom
heikkinen
et
al
clement
et
al
oseltamivir
treatment
influenza
children
year
age
appear
abl
reduc
risk
aom
first
day
ill
rr
ci
benefit
even
larger
younger
children
age
year
age
reduct
risk
aom
first
day
rr
ci
whitley
et
al
pathogenesi
aom
influenza
could
result
viral
infect
middl
ear
infect
eustachian
tube
result
occlus
infect
nasopharynx
result
inflamm
produc
eustachian
tube
dysfunct
addit
studi
need
done
understand
pathogenesi
influenza
induc
aom
influenza
result
sinu
middl
ear
involv
clinic
studi
suggest
influenza
vaccin
may
especi
use
otiti
prone
children
specif
antivir
therapi
may
benefici
prevent
otiti
media
healthi
well
otiti
prone
children
area
need
studi
effect
specif
antivir
therapi
insert
pe
tube
adenoidectomi
million
bilater
pe
tube
place
adenoid
without
tonsillectomi
perform
children
year
paradis
bear
drug
could
reduc
use
procedur
could
result
larg
cost
save
deserv
investig
statu
rsv
fusion
inhibitor
dan
viropharma
exton
pa
current
approv
therapi
rsv
ribavirin
limit
activ
substanti
toxic
viropharma
novel
antirsv
fusion
inhibitor
potent
ribavirin
viral
cytopath
effect
cpe
assay
rsv
inhibit
earli
fusion
event
document
time
drug
addit
studi
interact
conserv
pneumovir
target
fusion
protein
zhao
et
al
highli
potent
rsva
b
strain
ec
mm
viral
cpe
assay
specif
rsv
inhibit
replic
common
viral
respiratori
pathogen
clinic
isol
rsv
collect
past
year
north
america
europ
inhibit
concentr
mm
markedli
inhibit
viru
yield
rsv
antigen
express
cell
cultur
compound
also
efficaci
vivo
cotton
rat
model
rsv
infect
deliv
small
particl
aerosol
escap
mutant
analysi
identifi
conserv
fusion
protein
target
inhibit
initi
clinic
studi
progress
sever
rsv
fusion
inhibitor
current
develop
wyethayerst
janssen
pharmaceut
trimeri
bristol
meyer
squibb
pleconaril
novel
capsid
binder
broad
antipicornavir
activ
drug
intercal
hydrophob
pocket
protein
inhibit
attach
andor
uncoat
viru
absolut
bioavail
unclear
oral
pleconaril
show
doseproportion
increas
plasma
concentr
increas
oral
dose
abdelrahman
kearn
ingest
food
significantli
increas
oral
absorpt
compar
fast
state
high
fat
meal
appear
increas
c
max
auc
nonfatti
meal
appear
increas
level
lesser
extent
pharmacokinet
studi
abdelrahman
kearn
et
al
shown
drug
achiev
maximum
plasma
level
h
rang
h
maximum
concentr
mgml
drug
extens
protein
bound
exhibit
larg
volum
distribut
lkg
result
high
membran
permeabl
lipophil
characterist
rhode
liu
metabol
extens
metabolit
excret
urin
fece
none
metabolit
appear
signific
antivir
activ
pleconaril
exhibit
bimod
elimin
pattern
short
h
initi
account
drug
prolong
mean
h
termin
remaind
signific
alter
pleconaril
pharmacokinet
increas
age
gender
rhode
liu
minim
interact
isoenzym
vitro
studi
rhode
et
al
drug
interact
document
theophyllin
hinck
et
al
four
recent
trial
two
phase
two
phase
pleconaril
treatment
picornavir
respiratori
infect
complet
past
year
first
two
studi
enrol
patient
age
least
one
respiratori
symptom
system
symptom
present
within
h
onset
vri
symptom
fever
allow
cold
specif
sought
studi
picornaviru
pcr
posit
patient
patient
receiv
pleconaril
mg
tid
day
studi
medic
well
toler
common
side
effect
diarrhea
nausea
abdomin
pain
headach
slightli
common
treat
patient
placebo
group
retrospect
analysi
picornavirusinfect
enrolle
n
two
phase
studi
found
earli
pleconaril
therapi
associ
statist
signific
reduct
ill
durat
total
symptom
score
number
tissu
use
percent
night
disturb
sleep
day
reduct
time
allevi
symptom
vs
day
p
two
phase
studi
enrol
patient
n
older
year
old
symptom
durat
less
h
felt
cold
day
present
moder
sever
rhinorrhea
plu
least
one
respiratori
symptom
fever
patient
also
receiv
pleconaril
mg
tid
day
placebo
percentag
patient
posit
picornavirus
substanti
higher
studi
intenttotreatinfect
popul
aggreg
median
time
allevi
ill
day
shorter
treat
patient
vs
day
p
b
two
studi
improv
note
within
h
start
treatment
monitor
symptom
rhinorrhea
cough
sore
throat
nasal
congest
malais
myalgia
first
studi
pleconaril
well
toler
slightli
headach
nausea
vomit
placebo
also
note
small
increas
total
cholesterol
mgdl
pleconaril
vs
mgdl
placebo
platelet
count
mm
vs
mm
treat
arm
end
treatment
compar
baselin
pleconaril
gener
well
toler
medic
repres
first
effect
antivir
therapi
rhinoviru
cold
studi
progress
plan
assess
therapeut
valu
children
patient
increas
risk
rhinoviru
complic
eg
asthma
copd
prophylact
efficaci
current
review
food
drug
administr
possibl
approv
treatment
picornavir
respiratori
infect
patient
age
year
search
drug
activ
picornavirus
continu
proteas
matthew
et
al
identifi
import
target
lack
similar
human
proteas
essenti
replic
highli
conserv
activ
site
ruprintrivir
current
investig
highli
potent
mean
test
serotyp
nm
peptidomimet
irrevers
proteas
inhibitor
dragovich
et
al
dragovich
et
al
b
virus
ruprintrivir
potent
inhibit
viru
strain
test
compar
pleconaril
pirodavir
maintain
activ
broad
spectrum
divers
panel
relat
picornavirus
recent
challeng
experi
undertaken
subject
inocul
hrv
hank
treat
placebo
ruprintrivir
mg
intranas
h
prior
infect
prophylaxi
arm
h
challeng
treatment
arm
volunt
given
prophylaxi
receiv
studi
drug
either
twice
five
time
day
treatment
arm
subject
receiv
studi
drug
five
time
day
prophylaxi
studi
intranas
ruprintrivir
prevent
experiment
rhinoviru
infect
moder
ill
frequenc
sever
initi
rhinoviru
exposur
earli
treatment
also
result
viral
titer
done
either
cultur
rtpcr
ruprintrivir
subject
consist
rapid
declin
rel
placebo
medic
well
toler
without
signific
advers
event
note
result
perform
experiment
human
rhinoviru
infect
intranas
rupritrivir
test
patient
present
within
h
onset
coldlik
symptom
studi
fail
find
signific
differ
mean
respiratori
total
symptom
score
day
time
resolut
respiratori
cold
symptom
ruprintrivir
placebo
howev
enrolle
picornaviru
posit
retrospect
analysi
suggest
symptom
reduc
picornavirusposit
patient
enrol
within
h
symptom
onset
futur
studi
drug
focu
clinic
trial
design
measur
antivir
activ
clinic
benefit
start
earlier
time
point
search
altern
intranas
formul
potenti
effect
deliveri
site
action
recent
class
oral
bioavail
pyridon
proteas
inhibitor
develop
studi
novel
proteas
inhibitor
plan
determin
potenti
potent
broadspectrum
antipicornaviru
antivir
clinic
practic
iv
intern
symposium
respiratori
viral
infect
success
summar
recent
advanc
respiratori
viru
research
advanc
understand
epidemiolog
pathogenesi
rsv
influenza
parainfluenza
adenoviru
discuss
clear
emerg
evid
influenza
viru
deriv
avian
precursor
probabl
adapt
human
soon
pandem
introduct
novel
strain
influenza
region
around
hong
kong
concern
may
result
futur
pandem
influenza
vaccin
proven
costeffect
patient
popul
sever
studi
shown
respiratori
viral
infect
differenti
clinic
present
rapid
diagnost
test
aid
diagnost
process
respiratori
virus
clearli
implic
pathogenesi
frequenc
aom
hmpv
recent
discov
appear
common
pathogen
man
understand
viru
infanc
futur
studi
epidemiolog
pathogenesi
prevent
manag
like
present
futur
meet
mani
advanc
field
respiratori
viral
vaccinolog
past
year
rsv
vaccin
studi
adult
appear
safe
immunogen
parainfluenzaviru
vaccin
also
develop
appear
safe
immunogen
influenza
vaccin
found
costbenefici
patient
popul
therefor
recommend
patient
long
vaccin
avail
permit
complet
vaccin
highrisk
patient
sever
intranas
influenza
vaccin
either
approv
far
along
develop
past
year
mark
avail
new
antivir
agent
flunet
repres
novel
dimer
zanamivir
pharmacokinet
properti
anim
suggest
administ
onceaweek
sever
rsv
fusion
inhibitor
develop
class
agent
highli
potent
rsva
b
strain
current
undergo
earli
clinic
trial
two
new
class
antipicornaviru
agent
test
capsidbind
pleconaril
well
toler
effect
therapi
rhinoviru
cold
picornaviru
proteas
inhibitor
ruprintrivir
current
investig
highli
potent
peptidomimet
irrevers
proteas
inhibitor
drug
perform
well
experiment
human
rhinoviru
infect
result
signific
differ
treatment
natur
infect
still
investig
differ
set
novel
formul
